WO2019158019A1 - 嘧啶并环化合物及其制备方法和应用 - Google Patents
嘧啶并环化合物及其制备方法和应用 Download PDFInfo
- Publication number
- WO2019158019A1 WO2019158019A1 PCT/CN2019/074685 CN2019074685W WO2019158019A1 WO 2019158019 A1 WO2019158019 A1 WO 2019158019A1 CN 2019074685 W CN2019074685 W CN 2019074685W WO 2019158019 A1 WO2019158019 A1 WO 2019158019A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- group
- formula
- compound
- unsubstituted
- Prior art date
Links
- 0 CC(C)(CC1(C)C)C(*)(*)*(*)(*)C(*)(*)CN1c1ncc(**)c2ncc[n]12 Chemical compound CC(C)(CC1(C)C)C(*)(*)*(*)(*)C(*)(*)CN1c1ncc(**)c2ncc[n]12 0.000 description 33
- JZIVWQKXVBAHJG-UHFFFAOYSA-N Clc1cccc(Sc(c2ncc[n]22)cnc2Cl)c1Cl Chemical compound Clc1cccc(Sc(c2ncc[n]22)cnc2Cl)c1Cl JZIVWQKXVBAHJG-UHFFFAOYSA-N 0.000 description 2
- IIZLAHCZLMDISQ-UHFFFAOYSA-N C=Nc1cccc2c1NNN2 Chemical compound C=Nc1cccc2c1NNN2 IIZLAHCZLMDISQ-UHFFFAOYSA-N 0.000 description 1
- DEHBOJCGXFJWJP-UHFFFAOYSA-N CC(C(N(CCCC1)C1=N1)=O)=C1O Chemical compound CC(C(N(CCCC1)C1=N1)=O)=C1O DEHBOJCGXFJWJP-UHFFFAOYSA-N 0.000 description 1
- MTHIEZLVFRDEDH-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CN1c([n]1c2ncc1)ncc2Sc(cccc1Cl)c1Cl)=O Chemical compound CC(C)(C)OC(NC(CC1)CN1c([n]1c2ncc1)ncc2Sc(cccc1Cl)c1Cl)=O MTHIEZLVFRDEDH-UHFFFAOYSA-N 0.000 description 1
- KPVGSBWJGVRKFU-UHFFFAOYSA-N CC(C)(C)OC(Nc(cc1)nc(Cl)c1Cl)=O Chemical compound CC(C)(C)OC(Nc(cc1)nc(Cl)c1Cl)=O KPVGSBWJGVRKFU-UHFFFAOYSA-N 0.000 description 1
- NFKDYKJQSRILEG-UHFFFAOYSA-N CC(C)(C)OC(Nc(cc1I)nc(Cl)c1Cl)=O Chemical compound CC(C)(C)OC(Nc(cc1I)nc(Cl)c1Cl)=O NFKDYKJQSRILEG-UHFFFAOYSA-N 0.000 description 1
- AUOPOSIUTYXMJT-XAEBCRAKSA-N CC(C)(C)S(N(C)[C@H](CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc1cccc(Cl)c1Cl)=O Chemical compound CC(C)(C)S(N(C)[C@H](CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc1cccc(Cl)c1Cl)=O AUOPOSIUTYXMJT-XAEBCRAKSA-N 0.000 description 1
- AUOPOSIUTYXMJT-HWKNZQKHSA-N CC(C)(C)[S@@](N(C)C(CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc(cccc1Cl)c1Cl)=O Chemical compound CC(C)(C)[S@@](N(C)C(CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc(cccc1Cl)c1Cl)=O AUOPOSIUTYXMJT-HWKNZQKHSA-N 0.000 description 1
- WOGSQSXCCMRPSY-GOKJBEJGSA-N CC(C)(C)[S@@](N[C@H](CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc(cccc1Cl)c1Cl)=O Chemical compound CC(C)(C)[S@@](N[C@H](CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc(cccc1Cl)c1Cl)=O WOGSQSXCCMRPSY-GOKJBEJGSA-N 0.000 description 1
- KJGAYZWDJJUMJR-DIFFPNOSSA-N CC(C)(C)[S@@](N[C@H](CCC1)C11CCNCC1)=O Chemical compound CC(C)(C)[S@@](N[C@H](CCC1)C11CCNCC1)=O KJGAYZWDJJUMJR-DIFFPNOSSA-N 0.000 description 1
- YLVMHUIJTYHFGX-NZSYBYGASA-N CC(C)(CC(CC1)CC1(CC1)CCN1c([n]1c2ncc1)ncc2Sc(cccc1Cl)c1Cl)[S@@](C)=O Chemical compound CC(C)(CC(CC1)CC1(CC1)CCN1c([n]1c2ncc1)ncc2Sc(cccc1Cl)c1Cl)[S@@](C)=O YLVMHUIJTYHFGX-NZSYBYGASA-N 0.000 description 1
- KLOCMICSYVASJK-HXUWFJFHSA-N CC(C)c(cccc1)c1Sc(c1nnc[n]11)cnc1N(CC1)CCC1(CCC1)[C@@H]1N Chemical compound CC(C)c(cccc1)c1Sc(c1nnc[n]11)cnc1N(CC1)CCC1(CCC1)[C@@H]1N KLOCMICSYVASJK-HXUWFJFHSA-N 0.000 description 1
- AAZKPPLFOAMYII-QVDQXJPCSA-N CC(C1)CC2(CCN(C)CC2)[C@@H]1N Chemical compound CC(C1)CC2(CCN(C)CC2)[C@@H]1N AAZKPPLFOAMYII-QVDQXJPCSA-N 0.000 description 1
- IOFHZTVTTCMZBZ-UHFFFAOYSA-N CC(CC1)(CCN1c([n]1ncnc11)ncc1Sc(cccc1Cl)c1Cl)N Chemical compound CC(CC1)(CCN1c([n]1ncnc11)ncc1Sc(cccc1Cl)c1Cl)N IOFHZTVTTCMZBZ-UHFFFAOYSA-N 0.000 description 1
- ULLMWEQEVXWLIQ-KPGICGJXSA-N CC(CC1)C(C)[C@@H]1N Chemical compound CC(CC1)C(C)[C@@H]1N ULLMWEQEVXWLIQ-KPGICGJXSA-N 0.000 description 1
- FGSADXNSDYTHJA-QVDQXJPCSA-N CC(CCC12CCN(C)CC1)[C@H]2N Chemical compound CC(CCC12CCN(C)CC1)[C@H]2N FGSADXNSDYTHJA-QVDQXJPCSA-N 0.000 description 1
- XVJRVYONDJGSLX-UHFFFAOYSA-N CC1N(C)C(C)CN(C)C1 Chemical compound CC1N(C)C(C)CN(C)C1 XVJRVYONDJGSLX-UHFFFAOYSA-N 0.000 description 1
- KVURBEPLMKLCHI-UHFFFAOYSA-N CC1c2ccccc2CC=C1 Chemical compound CC1c2ccccc2CC=C1 KVURBEPLMKLCHI-UHFFFAOYSA-N 0.000 description 1
- YZRPKTDJOUNZMV-UHFFFAOYSA-N CCOC(C(C(N(C=CC=C1)C1=N1)=O)=C1O)=O Chemical compound CCOC(C(C(N(C=CC=C1)C1=N1)=O)=C1O)=O YZRPKTDJOUNZMV-UHFFFAOYSA-N 0.000 description 1
- CUVGQTUFLMTENE-UHFFFAOYSA-N CCOC(C(C(N(CCCC1)C1=N1)=O)=C1O)=O Chemical compound CCOC(C(C(N(CCCC1)C1=N1)=O)=C1O)=O CUVGQTUFLMTENE-UHFFFAOYSA-N 0.000 description 1
- AVMOVYCJFGHJCM-UHFFFAOYSA-N CC[IH]c1cc(C)ccc1 Chemical compound CC[IH]c1cc(C)ccc1 AVMOVYCJFGHJCM-UHFFFAOYSA-N 0.000 description 1
- MQALLIZGZUVRRM-LJQANCHMSA-N CN(C)C(C(Nc1cccc(Sc(c2ncc[n]22)cnc2N(CC2)CCC2(CCC2)[C@@H]2N)c1Cl)=O)=O Chemical compound CN(C)C(C(Nc1cccc(Sc(c2ncc[n]22)cnc2N(CC2)CCC2(CCC2)[C@@H]2N)c1Cl)=O)=O MQALLIZGZUVRRM-LJQANCHMSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N CN(C)c1ccncc1 Chemical compound CN(C)c1ccncc1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- FRRDFNYQYUVJGQ-MRVPVSSYSA-N CN(CC1)CCC1(CC(C1)(F)F)[C@@H]1N Chemical compound CN(CC1)CCC1(CC(C1)(F)F)[C@@H]1N FRRDFNYQYUVJGQ-MRVPVSSYSA-N 0.000 description 1
- CRVZHKIXTZELOY-QMMMGPOBSA-N CN(CC1)CCC1(CC1)[C@H]1N Chemical compound CN(CC1)CCC1(CC1)[C@H]1N CRVZHKIXTZELOY-QMMMGPOBSA-N 0.000 description 1
- DHZPPKRYHTVMFP-SECBINFHSA-N CN(CC1)CCC1(CCC1)[C@@H]1N Chemical compound CN(CC1)CCC1(CCC1)[C@@H]1N DHZPPKRYHTVMFP-SECBINFHSA-N 0.000 description 1
- DHZPPKRYHTVMFP-VIFPVBQESA-N CN(CC1)CCC1(CCC1)[C@H]1N Chemical compound CN(CC1)CCC1(CCC1)[C@H]1N DHZPPKRYHTVMFP-VIFPVBQESA-N 0.000 description 1
- XDXNTVBNVTWPRF-VHSXEESVSA-N CN(CC1)CCC1(C[C@H](C1)OC)[C@@H]1N Chemical compound CN(CC1)CCC1(C[C@H](C1)OC)[C@@H]1N XDXNTVBNVTWPRF-VHSXEESVSA-N 0.000 description 1
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 1
- PWMCFVMTTVEMDS-SNVBAGLBSA-N CN[C@H](CCC1)C11CCN(C)CC1 Chemical compound CN[C@H](CCC1)C11CCN(C)CC1 PWMCFVMTTVEMDS-SNVBAGLBSA-N 0.000 description 1
- IUWYPCSCEYVSCQ-MEDUHNTESA-N C[C@@H]1OCC(CC2)(CCN2c([n]2c3ncc2)ncc3Sc(cc(N)nc2Cl)c2Cl)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c([n]2c3ncc2)ncc3Sc(cc(N)nc2Cl)c2Cl)[C@@H]1N IUWYPCSCEYVSCQ-MEDUHNTESA-N 0.000 description 1
- PPIYDJQJBMVTQW-BLLLJJGKSA-N C[C@@H]1OCC(CC2)(CCN2c([n]2c3ncc2)ncc3Sc(ccnc2N)c2Cl)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c([n]2c3ncc2)ncc3Sc(ccnc2N)c2Cl)[C@@H]1N PPIYDJQJBMVTQW-BLLLJJGKSA-N 0.000 description 1
- GIRUYQNHFAMADJ-SUMWQHHRSA-N C[C@@H]1OCC(CC2)(CCN2c([n]2ncnc22)ncc2Sc(ccnc2C)c2Cl)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c([n]2ncnc22)ncc2Sc(ccnc2C)c2Cl)[C@@H]1N GIRUYQNHFAMADJ-SUMWQHHRSA-N 0.000 description 1
- ZFXYCSYUXJDLKM-ABAIWWIYSA-N C[C@H]1OCC(CC2)(CCN2c([n]2c3nnc2)ncc3Sc(ccnc2N)c2Cl)[C@H]1N Chemical compound C[C@H]1OCC(CC2)(CCN2c([n]2c3nnc2)ncc3Sc(ccnc2N)c2Cl)[C@H]1N ZFXYCSYUXJDLKM-ABAIWWIYSA-N 0.000 description 1
- PSFJEBOCDYCPCB-UHFFFAOYSA-N Cc1cc(CCC2)c2c(I)c1 Chemical compound Cc1cc(CCC2)c2c(I)c1 PSFJEBOCDYCPCB-UHFFFAOYSA-N 0.000 description 1
- LZAQUDUBTTVFMV-LJQANCHMSA-N Cc1cccc(Sc(c2ncc[n]22)cnc2N(CC2)CCC2(CCC2)[C@@H]2N)c1 Chemical compound Cc1cccc(Sc(c2ncc[n]22)cnc2N(CC2)CCC2(CCC2)[C@@H]2N)c1 LZAQUDUBTTVFMV-LJQANCHMSA-N 0.000 description 1
- GIWQSPITLQVMSG-UHFFFAOYSA-N Cc1ncc[n]1C Chemical compound Cc1ncc[n]1C GIWQSPITLQVMSG-UHFFFAOYSA-N 0.000 description 1
- ZCHCHJQEWYIJDQ-UHFFFAOYSA-N Cc1ncc[o]1 Chemical compound Cc1ncc[o]1 ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N Cc1ncc[s]1 Chemical compound Cc1ncc[s]1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- VVAMQBINPBKJSI-OAHLLOKOSA-N Cc1nccc(Sc(c2nnc[n]22)cnc2N(CC2)CCC2(COC2)[C@@H]2N)c1Cl Chemical compound Cc1nccc(Sc(c2nnc[n]22)cnc2N(CC2)CCC2(COC2)[C@@H]2N)c1Cl VVAMQBINPBKJSI-OAHLLOKOSA-N 0.000 description 1
- SWYFTHGXEJSXEA-UHFFFAOYSA-N Clc(cccc1Sc(c2nnc[n]22)cnc2N(CC2)CCC22NCCC2)c1Cl Chemical compound Clc(cccc1Sc(c2nnc[n]22)cnc2N(CC2)CCC22NCCC2)c1Cl SWYFTHGXEJSXEA-UHFFFAOYSA-N 0.000 description 1
- ROAMIVNPSQYTSD-UHFFFAOYSA-N NCC(CC1)CN1c([n]1c2ncc1)ncc2Sc(cccc1Cl)c1Cl Chemical compound NCC(CC1)CN1c([n]1c2ncc1)ncc2Sc(cccc1Cl)c1Cl ROAMIVNPSQYTSD-UHFFFAOYSA-N 0.000 description 1
- AMFUYLGGRMKMSG-SSDOTTSWSA-N N[C@H](CC(C1)(F)F)C11CCNCC1 Chemical compound N[C@H](CC(C1)(F)F)C11CCNCC1 AMFUYLGGRMKMSG-SSDOTTSWSA-N 0.000 description 1
- FGXZYHJLEVUMLX-QGZVFWFLSA-N N[C@H](CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc(c(Cl)ccc1)c1Cl Chemical compound N[C@H](CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc(c(Cl)ccc1)c1Cl FGXZYHJLEVUMLX-QGZVFWFLSA-N 0.000 description 1
- HDTZYLROFJRIET-MRXNPFEDSA-N N[C@H](CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc1cc(N)ncc1Cl Chemical compound N[C@H](CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc1cc(N)ncc1Cl HDTZYLROFJRIET-MRXNPFEDSA-N 0.000 description 1
- LVTZMDOWVYKNIE-QGZVFWFLSA-N N[C@H](CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc1cccc(N)c1Cl Chemical compound N[C@H](CCC1)C1(CC1)CCN1c([n]1c2ncc1)ncc2Sc1cccc(N)c1Cl LVTZMDOWVYKNIE-QGZVFWFLSA-N 0.000 description 1
- ANNPHQWSGBWPJI-MRXNPFEDSA-N N[C@H](CCC1)C1(CC1)CCN1c([n]1c2nnc1)ncc2Sc(cccc1N)c1Cl Chemical compound N[C@H](CCC1)C1(CC1)CCN1c([n]1c2nnc1)ncc2Sc(cccc1N)c1Cl ANNPHQWSGBWPJI-MRXNPFEDSA-N 0.000 description 1
- ILEZIDQBUMKTQR-OAHLLOKOSA-N N[C@H](CCC1)C1(CC1)CCN1c([n]1c2nnc1)ncc2Sc1ncccc1 Chemical compound N[C@H](CCC1)C1(CC1)CCN1c([n]1c2nnc1)ncc2Sc1ncccc1 ILEZIDQBUMKTQR-OAHLLOKOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/30—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention discloses pyrimido-ring compounds, pharmaceutically acceptable salts, hydrates, prodrugs, stereoisomers, solvates thereof or isotopically-labeled compounds thereof.
- the present invention also provides a process for the preparation of such compounds and intermediate compounds thereof, compositions containing such compounds, and the use of such compounds for the preparation of a medicament for preventing and/or treating a disease or condition associated with abnormal SHP2 activity.
- the tyrosine phosphatase SHP2 consists of two N-terminal Src homology 2 domains (N-SH2 and C-SH2) and a protein tyrosine phosphatase catalytic domain (PTP).
- N-SH2 can bind to PTP to form a cyclic structure, which hinders the binding of PTP to the substrate, so that the catalytic activity of the enzyme is inhibited; when the tyrosine of the upstream receptor protein is phosphorylated, N- In combination with SH2, the PTP catalytic domain is released to exert phosphatase activity.
- SHP2 is involved in multiple tumor cell signaling pathways, such as RTK/Ras/MAPK, JAK/STAT, and PI3K/Akt, through functional roles downstream of the cytoplasm of many receptor tyrosine kinases.
- RTK/Ras/MAPK RTK/Ras/MAPK
- JAK/STAT JAK/STAT
- PI3K/Akt PI3K/Akt
- SHP2 is also involved in programmed death receptor 1 (PD1)-mediated immune system suppression.
- PD1 programmed death receptor 1
- SHP2 is capable of dephosphorylation of T cell intracellular antigen receptor pathway proteins, thereby inhibiting T cell activation.
- inhibition of SHP2 activity can reverse immunosuppression in the tumor microenvironment.
- SHP2 is an important member of the protein tyrosine phosphatase family and is associated with a variety of human diseases, such as Noonan Syndrome, Leopard Syndrome, adolescent myelomonocytic leukemia, and neuroblasts.
- the pyrimido-ring compound provided by the invention is a novel SHP2 inhibitor, exhibits good inhibitory activity against tumor cells and has good drug-forming properties, and has broad drug development prospects. Moreover, the preparation method of the compound is simple and is advantageous for industrial production.
- the present invention provides a pyrimido-ring compound of the formula (I), a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer or solvate thereof,
- Z 1 and Z 2 are simultaneously CH, or one of Z 1 and Z 2 is N and the other is CH;
- X is independently S or does not exist
- Y is independently C or N
- n is independently 0, 1, or 2;
- R 1 is independently 0-4 R 1a substituted phenyl groups, 0-4 R 1a substituted 1-4 azaheteroaryl groups, 0-4 R 1a substituted naphthyl groups, 0-4 R 1a substituted 1-4 aza naphthalene aryl, 0-4 R 1a substituted or unsubstituted benzoheterocyclyl, 0-4 R 1a substituted or unsubstituted containing 1-4 aza And a cycloalkyl group, 0-4 R 1a substituted heteroaryl groups having 1 to 4 N, NR 1b , O or S(O)m hetero atoms, R 1c substituted or unsubstituted C 1-8 alkyl group, Or R 1c substituted or unsubstituted C 1-8 haloalkyl; wherein m is selected from 0, 1 and 2;
- R 2a , R 2b , R 3a and R 3b are independently hydrogen or R 1a1 substituted or unsubstituted C 1-4 alkyl;
- R 4 is independently hydrogen, or R 1a1 substituted or unsubstituted C 1-4 alkyl; R 5 is absent;
- R 2a , R 2b , R 3a , R 3b , R 4 and R 5 together with the attached carbon and Y form 0-3 R 4a substituted 3 to 7 membered cycloalkyl groups
- 0-3 R 4a substituted 3 to 7 membered heterocycloalkyl wherein the 3 to 7 membered heterocycloalkyl, the hetero atom is selected from one or more of N, O and S, The number of the hetero atoms is 1-3;
- R 1b is independently hydrogen, or R 1a1 substituted or unsubstituted C 1-4 alkyl
- R 4a is independently hydrogen, halogen, R 1a1 substituted or unsubstituted C 1-4 alkoxy, R 1a1 substituted or unsubstituted C 1-4 alkyl, hydroxy, amino or C 1-4 alkylamino;
- R 1a1 is independently halogen or C 1-4 alkyl
- R 1a2 and R 1a3 are independently hydrogen or C 1-4 alkyl
- the definition of some substituents in the pyrimido-ring compound represented by the formula (I) can be as follows, and the definition of the substituent not mentioned is as defined in any one of the above schemes.
- Z 1 , Z 2 are both C or one of them is N;
- X is independently S or does not exist
- Y is independently C or N
- n is independently 0, 1, or 2;
- R 1 is independently 0 to 4 R 1a substituted phenyl groups, 0 to 4 R 1a substituted 1-4 azaheteroaryl groups, 0 to 4 R 1a substituted naphthyl groups, 0 to 4 R 1a substituted 1-4 azanaphthalene aryl groups, 0 to 4 R 1a substituted or unsubstituted benzoheterocyclic rings, 0 to 4 R 1a substituted or unsubstituted 1-4 aza heteroaryls Ring, 0 to 4 R 1a substituted heteroaryl rings containing 1-4 N, NR 1b , O or S(O) m hetero atoms, R 1c substituted or unsubstituted C 1-8 alkyl, R 1csubstituted or unsubstituted C 1-8 haloalkyl; wherein m is selected from 0, 1 and 2;
- R 1b is independently hydrogen, R 1a1 substituted or unsubstituted C 1-4 alkyl;
- R 2a , R 2b , R 3a and R 3b are independently hydrogen, R 1a1 substituted or unsubstituted C 1-4 alkyl;
- R 4 is independently hydrogen, R 1a1 substituted or unsubstituted C 1-4 alkyl; R 5 is absent;
- R 4a is independently hydrogen, halogen, R 1a1 substituted or unsubstituted C 1-4 alkoxy, R 1a1 substituted or unsubstituted C 1-4 alkyl, hydroxy, amino, C 1-4 alkylamino.
- Z 1 is C, Z 2 is N or Z 1 is N, and Z 2 is C;
- X is independently S or does not exist
- Y is independently C or N
- n is independently 0, 1, or 2;
- R 1 is independently 0-4 R 1a substituted phenyl groups, 0-4 R 1a substituted 1-4 azaheteroaryl groups, 0-4 R 1a substituted naphthyl groups, 0-4 R 1a substituted with 1-4 aza naphthalene aryl groups, 0-4 R 1a substituted or unsubstituted benzoheterocyclic rings, 0-4 R 1a substituted or unsubstituted containing 1-4 aza heteroaryls Ring, 0-4 R 1a substituted heteroaryl rings containing 1-4 N, NR 1b , O or S(O)m heteroatoms, R 1c substituted or unsubstituted C 1-8 alkyl, R 1c a substituted or unsubstituted C 1-8 haloalkyl; wherein m is selected from 0, 1 and 2;
- R 1b is independently hydrogen, R 1a1 substituted or unsubstituted C 1-4 alkyl;
- R 2a , R 2b , R 3a and R 3b are independently hydrogen, R 1a1 substituted or unsubstituted C 1-4 alkyl;
- R 4 is independently hydrogen, R 1a1 substituted or unsubstituted C 1-4 alkyl; R 5 is absent;
- R 4a is independently hydrogen, halogen, R 1a1 substituted or unsubstituted C 1-4 alkoxy, R 1a1 substituted or unsubstituted C 1-4 alkyl, hydroxy, amino, C 1-4 alkylamino.
- the pyrimido-ring compound structure represented by the formula (I) according to the present invention is as shown in the formula (II).
- Z 1 is C and Z 2 is N, or Z 1 is N and Z 2 is C.
- the pyrimido-ring compound structure represented by the formula (I) according to the present invention is as shown in the formula (III).
- the pyrimido-ring compound represented by the formula (I) according to the present invention has a structure as shown in the formula (I-A).
- the pyrimido-ring compound of the formula (I) according to the present invention has a structure as shown in the formula (II-A).
- the pyrimido-ring compound structure represented by the formula (I) according to the present invention is as shown in the formula (I-B).
- R 4 and R 5 together with the linking carbon are selected from the following structures:
- the pyrimido-ring compound structure represented by the formula (I) according to the present invention is represented by the formula I-B.
- R 4 and R 5 together with the linking carbon are selected from the following structures:
- the pyrimido-ring compound structure represented by the formula (I) of the present invention is represented by the formula II-B.
- R 4 and R 5 together with the linking carbon are selected from the following structures:
- the pyrimido-ring compound structure represented by the formula (I) according to the present invention is as shown in the formula (I-C).
- the pyrimido-ring compound structure represented by the formula (I) according to the present invention is represented by the formula III-C.
- the pyrimido-ring compound structure represented by the formula (I) according to the present invention is represented by the formula II-C.
- the 0-4 R 1a substituted phenyl groups are Wherein o is independently 0, 1, 2, 3 or 4, and the total number of R 1aa and R 1ab is 0-4, and R 1aa and R 1ab are as defined for R 1a .
- the 0-4 R 1a substituted naphthyl groups are Wherein o is independently 0, 1, 2, 3 or 4, and the total number of R 1aa and R 1ab is 0-4, and R 1aa and R 1ab are as defined for R 1a ; Ground
- the 0-4 R 1a substituted 1-4 aza aryl groups are Wherein o is independently 0, 1, 2, 3 or 4, and the total number of R 1aa and R 1ab is 0-4, and R 1aa and R 1ab are as defined in R 1a ; Containing from 1 to 4 azaheteroaryl groups; said 1-4 azaheteroaryl groups are preferably pyridyl groups (for example ), pyrimidinyl (for example ), pyrazinyl (for example) Or oxazinyl (for example) ).
- the 0-4 R 1a substituted 1-4 aza naphthalene aryl groups are Wherein, o is 0, 1, 2, 3 or 4, and the total number of R 1aa and R 1ab is 0-4, and the definitions of R 1aa and R 1ab are the same as those of R 1a ; Containing from 1 to 4 azaheteroaryl groups; said 1-4 azanaphthalenyl groups are preferably quinolyl groups (for example ).
- the 0-4 R 1a substituted or unsubstituted 1-4 azaheterocyclyl groups are Wherein, o is 0, 1, 2, 3 or 4, and the total number of R 1aa and R 1ab is 0-4, and the definitions of R 1aa and R 1ab are the same as those of R 1a ; Containing from 1 to 4 azaheterocyclyl groups, wherein Containing 1-4 azaheteroaryl groups, Is a heteroaryl group containing 1-4 N, NR 1b , O or S(O)m heteroatoms; the 1-4 azaaryl ring group is preferably 1H-pyrrolo[2, 3-b]pyridine (for example ).
- the 0-4 R 1a substituted heteroaryl groups containing 1-4 N, NR 1b , O or S(O)m heteroatoms are Wherein, o is 0, 1, 2, 3 or 4, and the total number of R 1aa and R 1ab is 0-4, and the definitions of R 1aa and R 1ab are the same as those of R 1a ; Containing 1-4 N, NR 1b, O, or S (O) m heteroaryl hetero atom; said containing 1-4 N, NR 1b, O, or S (O) m heteroaryl heteroatoms
- the base is preferably a heteroaryl group containing from 1 to 3 N, NR 1b , O or S(O)m heteroatoms, more preferably an imidazolyl group (for example ), thiazolyl (eg ), oxazolyl (for example) ), thiadiazolyl (eg Or benzothiazolyl (for example) ).
- the R 1c is substituted or unsubstituted C 1-8 alkyl and R 1c is substituted or unsubstituted C 1-8 haloalkyl, C 1-8 alkyl and the C haloalkyl of 1-8 C 1-8 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2 -Methylbutyl, 2,2-dimethylpropyl, n-hexyl, heptyl, 2-methylhexyl, 3-methylhexyl or octyl) may independently be a C 1-6 alkyl group (eg, A Base, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, iso
- the halogen in the R 1c substituted or unsubstituted C 1-8 haloalkyl group, may be fluorine, chlorine, bromine or iodine.
- the number of halo groups may be 1, 2, 3, 4, 5 or 6.
- the C 1-4 alkyl group in the R 1a1 substituted or unsubstituted C 1-4 alkyl group, may be methyl, ethyl, n-propyl, isopropyl, N-butyl, isobutyl, sec-butyl or tert-butyl; preferably methyl.
- the aryl group is a C 6 -C 10 aryl group, preferably a phenyl or naphthyl group.
- R 4 and/or R 5 is C 1-4 alkyl, -OC 1-4 alkyl, C 1-4 alkyl substituted amino, or -OC 1-4 alkane
- the C 1-4 alkyl group may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
- the C 1-4 alkoxy group may be a methyloxy group, an ethyloxy group, or a positive Propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, sec-butyloxy or tert-butyloxy.
- said 3 to 7 membered cycloalkyl eg, cyclopropyl
- a cyclobutyl group for example, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl
- cyclopentyl for example
- cyclohexyl for example
- said 3 to 7 membered heterocycloalkyl group can be a 5-6 membered heterocycloalkyl group, wherein the hetero atom is selected from one or more of N, O and S, and the number of the hetero atom is 1-2 Preferred; tetrahydrofuranyl (for example Or pyrrolidinyl (for example) ).
- two adjacent groups in R 2a , R 2b , R 3a , R 3b , R 4 and R 5 form 0-3 R 4a substitutions together with the attached carbon and Y.
- the 3- to 7-membered cycloalkyl group may be a cyclopentyl group (for example).
- halogen is fluoro, chloro, bromo or iodo; preferably fluoro or chloro .
- the C 1-4 alkoxy group in the R 1a1 substituted or unsubstituted C 1-4 alkoxy group, may be a methyloxy group, an ethyloxy group or a n-propyl group.
- the C 3-8 cycloalkyl group may be a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, Cyclohexyl, cycloheptyl or cyclooctyl; preferably cyclopropyl.
- said C 1-4 alkyl group may be A Base, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; preferably methyl.
- the C 1-4 alkyl group may be methyl, ethyl, n-propyl, isopropyl, n-butyl. , isobutyl, sec-butyl or tert-butyl.
- the alkenyl group in the substituted or unsubstituted alkenyl group, may be a C 2 -C 10 alkenyl group, preferably a C 2 -C 6 alkenyl group, for example Vinyl, 1-propenyl, allyl, but-1-enyl, but-2-enyl, pent-1-enyl or pentane-1,4-dienyl; preferably a vinyl group.
- the mono or C 3-12 heterocyclyl group, or a C 3-12 mono- or poly-substituted heterocyclic group or a C 3- 12 heterocyclyl group mono
- the hetero atom is selected from one or more of nitrogen, oxygen and sulfur, and the number of heteroatoms is from 1 to 4; preferably a monocyclic or bicyclic heterocyclic group, the hetero atom being selected from the group consisting of nitrogen, oxygen and One or more of sulfur, the number of heteroatoms is 1-2; for example
- the C 1-4 alkyl substituted amino group is NH(CH 3 ).
- the NR 1a2 R 1a3 is -NH 2 or N(CH 3 ) 2 .
- the substituted C 3-12 mono or polyheterocyclyl is N-(2-aminoethyl)-2-aminoethyl
- the 0-4 R 1a substituted phenyl groups are
- the 0-4 R 1a substituted 1-4 aza aryl groups are
- the 0-4 R 1a substituted or unsubstituted 1-4 azaheterocyclyl groups are
- the 0-4 R 1a substituted heteroaryl groups containing 1-4 N, NR 1b , O or S(O)m heteroatoms are
- the R 1c substituted C 1-8 alkyl group is
- R 2a , R 2b , R 3a and R 3b are independently hydrogen or methyl.
- R 4 is independently hydrogen or methyl; R 5 is absent.
- R 4 and R 5 are independently hydrogen, methyl, ethyl, phenyl, amino, methylamino or ethylamino.
- R 1 is selected from the following structures:
- the ring formed by R 4 and R 5 together with Y is selected from the following structures:
- R 4a is as defined above.
- the ring formed by R 4 and R 5 together with Y is selected from the following structures:
- R 4a is as defined above.
- the ring formed by R 4 and R 5 together with Y has the following configuration:
- the ring formed by R 4 and R 5 together with Y has the following configuration:
- two adjacent groups of said R 2a , R 2b , R 3a , R 3b , R 4 and R 5 form 0-3 together with the attached carbon and Y.
- the 0-3 R 4a substituted 3 to 7 membered cycloalkyl group is (E.g ).
- the compound is selected from any of the following compounds:
- the compound is selected from any of the following compounds:
- the present invention provides an isotope-labeled compound of a pyrimido-ring compound represented by formula (I), a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer or solvate thereof.
- a pharmaceutically acceptable salt hydrate, prodrug, stereoisomer or solvate thereof.
- the atoms which can be labeled with isotopes include, but are not limited to, hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, iodine and the like. They may be replaced by the isotopes 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 35 S, 36 Cl and 125 I, respectively.
- the invention also provides a preparation method of the pyrimido-ring compound represented by the formula (I) and an intermediate compound thereof, which mainly comprises the following aspects:
- the present invention provides a method for preparing a pyrimido-ring compound represented by formula (I), which comprises any of the following schemes;
- the compound F when X is absent, the compound F represents boric acid, mercaptan or sodium sulfide of R 1 ; when X is S, the compound F is a mercaptan or sodium sulfide;
- W 1 represents a halogen, preferably Br, I;
- X, Y, Z 1 , Z 2 , n, R 1 , R 2a , R 2b , R 3a , R 3b , R 4 and R 5 are as defined above;
- W 2 represents a halogen, preferably Cl, Br, I;
- Z 1 , Z 2 , X, Y, n, R 1 , R 2a , R 2b , R 3a , R 3b , R 4 and R 5 are as defined above State
- R 4Pg , R 5Pg together with the linking carbon Selected from the following structure:
- R 4 and R 5 together with the linking carbon are selected from the following structures:
- the pyrimido-ring compound represented by the formula (I) when it is a pyrimido-ring compound represented by the formula (I-C), it comprises the following steps:
- the pyrimido-ring compound represented by the formula (I) when it is a pyrimido-ring compound represented by the formula (I-A), it comprises the following steps:
- the sodium sulfide intermediate compound of the formula D and the halogenated product R 1 -W 1 are subjected to a coupling reaction as shown below to obtain a pyrimido-ring compound represented by the formula (IA), and the reaction equation is as follows:
- Y, n, W 1 , R 1 , R 2a , R 2b , R 3a , R 3b , R 4 and R 5 are as defined above.
- the preparation method of the compound I-B comprises the following steps:
- R 1 , R 2a , R 2b , R 3a , R 3b , R 4 , R 5 and R 4a are as defined above;
- R 4Pg , R 5Pg together with the linking carbon is selected from the following structures:
- R 4 and R 5 together with the linking carbon are selected from the following structures:
- F can be boric acid, mercaptan or sodium sulfur
- W 1 represents halogen, preferably Br, I;
- X, Y, F, Z 1 , Z 2 , n, R 1 , R 2a , R 2b , R 3a , R 3b , R 4 and R 5 are as defined above Said
- W 2 represents halogen, preferably Cl, Br, I;
- X, Y, n, R 1 , R 2a , R 2b , R 3a , R 3b , R 4 and R 5 are as defined above;
- the method comprises the following steps:
- the sodium sulphide intermediate compound D is coupled with a halogenated compound to obtain a pyrimido-ring compound as shown in the formula (II-A), and the reaction equation is as follows:
- R 4 and R 5 together with the linking carbon are selected from the following structures:
- X, n, R 1 , R 2a , R 2b , R 3a , R 3b , R 4 , R 5 and R 4a are as defined above; p is 0, 1, 2 or 3;
- R 1 , R 2a , R 2b , R 3a , R 3b , R 4 , R 5 , R 1a and R 1a4 are as defined above.
- the invention also provides a compound A,
- W 1 represents a halogen, preferably Br, I; and R 2a , R 2b , R 3a , R 3b , R 4 , R 5 , Y, n are as defined above.
- the compound A is represented by the compound A-II,
- the compound A is as shown in the compound A-III.
- the compound A-II is selected from any of the following structures:
- the compound A-III is selected from any of the following structures:
- the invention also provides a process for the preparation of a compound of formula A, which comprises the steps of:
- W 1 represents halogen, preferably Br, I
- W 2 represents halogen, preferably Cl, Br, I
- Y, n, R 2a , R 2b , R 3a , R 3b , R 4 and R 5 are as defined above .
- the method for preparing the compound A-II comprises the following steps:
- the method for preparing the compound A-III comprises the following steps:
- the invention also provides a compound as shown in formula C-1,
- the compound C-1 is selected from any of the following structures:
- the invention also provides a preparation method of the compound C-1, which comprises the following steps:
- Pg1 is selected from the group consisting of a protecting group Boc, a benzoyl group, a benzyl group; and Pg, U, q, n, R 2a , R 2b , R 3a , R 3b and R 4a are as defined above.
- the present invention also provides a compound as shown in Formula C-2,
- R 6 is independently C 1-8 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkenyl; U, q, Pg, n, R 2a , R 2b , R 3a , R 3b and The definition of R 4a is as described above.
- the compound C-2 is selected from any of the following structures:
- the invention also provides a preparation method of the compound C-2, comprising the following steps:
- the spirocyclic ketone compound C-1a is added with a R 6 -substituted nucleophilic reagent to obtain a hydroxy compound C-2a; the compound C-2a is converted into an amino compound C-2b by a Ritter reaction, and then the protective group Pg1 is selectively removed.
- C-2 the reaction equation is as follows:
- R 6 , U, q, Pg1, Pg, n, R 2a , R 2b , R 3a , R 3b and R 4a are as defined above.
- the invention also provides a compound as shown in formula C-3,
- R 6 , Pg, n, R 2a , R 2b , R 3a and R 3b are as defined above.
- the compound C-3 is:
- the invention also provides a preparation method of the compound C-3, comprising the following steps:
- R 6 , Pg1, Pg, n, R 2a , R 2b , R 3a and R 3b are as defined above.
- the present invention also provides a compound of the formula C-4,
- R 6 , Pg, n, R 2a , R 2b , R 3a and R 3b are as defined above;
- the compound C-4 is selected from any of the following structures:
- the invention also provides a preparation method of the compound C-4, comprising the following steps:
- Pg1, Pg, R 6 , n, R 2a , R 2b , R 3a and R 3b are as defined above.
- the invention also provides a compound of formula E,
- W 1 represents a halogen, preferably Br, I
- W 2 represents a halogen, preferably Cl, Br, I.
- compound E is as shown in the following formula E-II:
- compound E is as shown in the following formula E-III:
- the compound E-II is selected from any of the following structures:
- the compound E-III is selected from any of the following structures:
- the invention also provides a preparation method of the compound E-II, which comprises the steps of: halogenating the hydroxy intermediate B-3 to obtain a dihalogen-substituted compound E-II, and the reaction equation is as follows:
- W 1 represents a halogen, preferably Br, I
- W 2 represents a halogen, preferably Cl, Br, I.
- the invention also provides a preparation method of the compound E-III, which comprises the steps of: 4-chloropyrimidine compound E-1-III is substituted by hydrazine to obtain intermediate E-2-III; intermediate E-2-III is condensed and cyclized to obtain Halogenated intermediate E-III, the reaction equation is as follows:
- W 1 and W 2 are as described above.
- the present invention also provides a compound represented by Formula F-1, such as the compound of Formula F-1c;
- V is independently C or N; and R 1a is as defined above.
- the compound F-1 is selected from any of the following structures:
- the compound F-1C is selected from any of the following structures:
- the invention also provides a preparation method of the compound F-1, which comprises the following steps:
- halogenated compound F-1a and methyl mercaptopropionate are subjected to catalytic coupling to obtain intermediate F-1b-1, and then the corresponding sodium sulfide compound F-1c is obtained under basic conditions, and then F is obtained under acidic conditions. -1; or halogenated compound F-1a and tert-butyl sulfide (such as sodium t-butoxide) substituted to give intermediate F-1b-2, and then under acidic conditions to obtain F-1;
- W 3 is a halogen, preferably Br, I; and V, R 1a are as defined above.
- the invention also provides a compound as shown in formula B,
- W 2 represents a halogen, preferably Cl, Br, I; and R 1 and X are as defined above.
- the invention also provides a compound as shown in formula B-II,
- W 2 represents a halogen, preferably Cl, Br, I; and R 1 and X are as defined above.
- the compound B-II is selected from any of the following structures:
- the invention also provides a preparation method of the compound B-II, comprising the following steps:
- the dichloropyrimidine compound B-1-II is substituted with an amine to obtain the intermediate B-2-II; the intermediate B-2-II is condensed and cyclized under strong acid conditions and hydrolyzed to obtain a halogenated intermediate B-3-II; The intermediate B-3-II is subjected to catalytic coupling to give the intermediate B-4-II, which is then converted to the intermediate B-II.
- the reaction equation is as follows:
- W 1 represents a halogen, preferably Br, I
- W 2 represents a halogen, preferably Cl, Br, I
- R 1 and X are as defined above.
- the invention also provides a compound of formula D,
- Y, n, R 2a , R 2b , R 3a , R 3b , R 4 and R 5 are as defined above.
- the invention also provides a compound as shown in formula D-II,
- Y, n, R 2a , R 2b , R 3a , R 3b , R 4 and R 5 are as defined above.
- the compound D is:
- the invention also provides a process for the preparation of a compound of formula D, comprising the steps of:
- W 1 represents a halogen, preferably Br, I;
- Y, n, R 2a , R 2b , R 3a , R 3b , R 4 and R 5 are as defined above.
- the method for preparing the compound as shown in formula D-II comprises the following steps:
- W 1 represents a halogen, preferably Br, I;
- Y, n, R 2a , R 2b , R 3a , R 3b , R 4 and R 5 are as defined above.
- the solvent to which the present invention relates is preferably an inert solvent, for example selected from the group consisting of dichloromethane, chloroform, 1,2-dichloroethane, dioxane, DMF, acetonitrile, DMSO, NMP, THF or a combination thereof.
- an inert solvent for example selected from the group consisting of dichloromethane, chloroform, 1,2-dichloroethane, dioxane, DMF, acetonitrile, DMSO, NMP, THF or a combination thereof.
- the base to which the present invention relates includes an organic base and an inorganic base.
- the organic base to which the present invention relates is preferably TEA, DIPEA or a combination thereof.
- the inorganic base to which the present invention relates is preferably sodium hydride, potassium carbonate, sodium carbonate, cesium carbonate, potassium t-butoxide, sodium t-butoxide, LiHMDS, LDA, butyl lithium or a combination thereof.
- the isotopically-labeled compound of the pyrimido-ring compound of the formula (I) according to the present invention can be produced by a synthetic method similar to the unlabeled compound, except that the unlabeled starting material and/or reagent is replaced with an isotope. Labeled starting materials and/or reagents.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a pyrimido compound of the formula (I), a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer or solvate thereof or pyrimidine ring of the formula (I)
- the pharmaceutically acceptable excipient is preferably selected from the group consisting of a diluent, an absorbent, a wetting agent, a binder, a disintegrant, and a lubricant.
- the present invention also provides the pyrimido-ring compound represented by the formula (I), a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer or solvate thereof or pyrimidine ring of the formula (I)
- a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer or solvate thereof or pyrimidine ring of the formula (I)
- Use of an isotopically labeled compound of a compound, a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer or solvate thereof for the manufacture of a medicament for the treatment of a disease or condition associated with an abnormality in SHP2 activity.
- the disease or condition includes, but is not limited to, including Noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer Colon cancer, head cancer, neuroblastoma, squamous cell carcinoma of the head and neck, gastric cancer, anaplastic large cell lymphoma or glioblastoma.
- the present invention also provides a pharmaceutical preparation comprising the pyrimido compound represented by the formula (I), a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer or solvate thereof or the formula thereof (I)
- suspensions, syrups, emulsions, solutions, etc. in the form of liquids and spray-dried dispersions, for oral, sublingual, including subcutaneous, intravenous, intramuscular, intrasternal injection, injection, etc.
- Nasal administration such as nasal inhalation
- topical surfaces such as creams and ointments
- rectal administration such as suppositories
- the compounds disclosed herein may be administered alone or together with a suitable pharmaceutical carrier.
- the present invention also provides that the pharmaceutical preparation described in the preceding aspect can be formulated into an appropriate pharmaceutical dosage to facilitate and control the dosage of the drug.
- the dosage regimen of the compounds disclosed herein varies according to specific factors, such as pharmacodynamics and manner of administration, subject, sex, age, health status, weight of the subject, condition, other concurrent medication, medication Frequency, liver and kidney function, and the effect you want to achieve.
- the compounds disclosed herein may be administered in a single dose per day or in multiple doses (e.g., two to four times per day).
- the present invention also provides a pyrimido-ring compound represented by the formula (I), a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer or solvate thereof or a pyrimido compound of the formula (I), A product of a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer or a solvate thereof, for use in combination with other drugs selected from the group consisting of: anticancer drugs, tumor immunopharmaceuticals, antiallergic agents Medicines, antiemetics, analgesics, cytoprotective drugs, etc., have a better effect.
- the present invention also provides a pyrimido-ring compound represented by the formula (I), a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer or solvate thereof or a pyrimido compound of the formula (I),
- a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer or solvate thereof in combination with other drugs selected from the group consisting of anticancer drugs, tumor immunopharmaceuticals, antiallergic agents Medicines, antiemetics, analgesics, cytoprotective drugs, etc., have a better effect.
- the pyrimido-ring compounds disclosed herein are a novel class of allosteric inhibitors which are capable of inhibiting their activity by binding to the non-catalytic region of SHP2 and "locking" the basal state in which SHP2 activity is weak.
- the pyrimido-ring compound disclosed by the invention overcomes the shortcomings of the general selectivity and the medicinal property of the PTP-catalyzed regional inhibitor, and exhibits good biological activity and drug-forming property, and has good prospects for drug development.
- the terms "containing” or “including” may be open, semi-closed, and closed. In other words, the terms also include “consisting essentially of,” or “consisting of.”
- the reaction can be carried out and purified using the manufacturer's instructions for use of the kit, or in a manner well known in the art or as described in the present invention.
- the above techniques and methods can generally be carried out according to conventional methods well known in the art, as described in the various summaries and more specific references cited and discussed in this specification.
- the group and its substituents can be selected by those skilled in the art to provide stable structural moieties and compounds.
- the substituent When a substituent is described by a conventional chemical formula written from left to right, the substituent also includes the chemically equivalent substituent obtained when the structural formula is written from right to left. For example, -CH 2 O- is equivalent to OCH 2 -.
- C1-6 alkyl refers to an alkyl group as defined below having a total of 1, 2, 3, 4, 5 or 6 carbon atoms.
- the total number of carbon atoms in the simplified symbol does not include carbon that may be present in the substituents of the group.
- the numerical ranges defined in the substituents such as 0 to 4, 1-4, 1 to 3, 1-6, etc. indicate integers within the range, such as 0, 1, 2, 3, 4, 5, 6.
- halogen means fluoro, chloro, bromo or iodo.
- Haldroxy means an -OH group.
- Alkoxy means an alkyl group as defined below which is substituted by a hydroxy group (-OH).
- Cyano means -CN.
- Amino means -NH 2 .
- Substituted amino means an amino group substituted with one or two alkyl, alkylcarbonyl, aralkyl, heteroaralkyl groups as defined below, for example, monoalkylamino, dialkylamino, alkyl Amido, aralkylamino, heteroarylalkylamino.
- Carboxyl means -COOH.
- alkyl means a fully saturated straight or branched hydrocarbon chain group, It consists solely of carbon atoms and hydrogen atoms, has, for example, 1 to 12 (preferably 1 to 8, more preferably 1 to 6) carbon atoms, and is attached to the rest of the molecule by a single bond, for example including but not limited to Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl , n-hexyl, heptyl, 2-methylhexyl, 3-methylhexyl, octyl, decyl and decyl.
- the term "alkyl” means a fully saturated straight or branched hydrocarbon chain group, It consists solely of carbon atoms and hydrogen atoms, has, for example, 1 to 12 (preferably 1 to
- alkenyl as a group or part of another group means consisting only of carbon atoms and hydrogen atoms, containing at least one double bond, having for example 2-14 (preferably 2-10) And more preferably 2 to 6 carbon atoms and a straight or branched hydrocarbon chain group attached to the remainder of the molecule by a single bond, such as, but not limited to, vinyl, propenyl, allyl, butyl- 1-Alkenyl, but-2-enyl, pent-1-enyl, pentane-1,4-dienyl and the like.
- cycloalkyl as a group or part of another group means a stable non-aromatic monocyclic or polycyclic hydrocarbon group consisting solely of carbon atoms and hydrogen atoms, which may include a fused ring. a system, bridged ring system or spiro ring system having from 3 to 15 carbon atoms, preferably from 3 to 10 carbon atoms, more preferably from 3 to 8 carbon atoms, and which is saturated or unsaturated and may be via any suitable
- the carbon atom is attached to the rest of the molecule by a single bond. Unless otherwise specifically indicated in the specification, a carbon atom in a cyclic hydrocarbon group may be optionally oxidized.
- cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, 1H-indole Base, 2,3-indanyl, 1,2,3,4-tetrahydro-naphthyl, 5,6,7,8-tetrahydro-naphthyl, 8,9-dihydro-7H-benzo Cycloheptene-6-yl, 6,7,8,9-tetrahydro-5H-benzocycloheptenyl, 5,6,7,8,9,10-hexahydro-benzocyclooctenyl, Indenyl, bicyclo[2.2.1]heptyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, bi
- cycloalkyl as a group or part of another group means a saturated monocyclic or polycyclic hydrocarbon group consisting solely of carbon atoms and hydrogen atoms, which may include a bridged ring system or a snail. a ring system having from 3 to 15 carbon atoms, preferably from 3 to 10 carbon atoms, more preferably from 3 to 7 carbon atoms, and which may be attached to the remainder of the molecule via a single bond via any suitable carbon atom. It may include a coaxial connection or a spiral connection.
- cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl and the like.
- heterocyclyl as a group or part of another group means a heteroatom consisting of 2 to 14 carbon atoms and 1 to 6 heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur.
- a heterocyclic group may be a monocyclic, bicyclic, tricyclic or more cyclic ring system, which may include a fused ring system, a bridged ring system or a spiro ring system;
- the nitrogen, carbon or sulfur atom may optionally be oxidized; the nitrogen atom may optionally be quaternized; and the heterocyclic group may be partially or fully saturated.
- the heterocyclic group may be attached to the remainder of the molecule via a carbon atom or a hetero atom and through a single bond.
- one or more of the rings may be an aryl or heteroaryl group as defined hereinafter, provided that the point of attachment to the rest of the molecule is a non-aromatic ring atom.
- the heterocyclic group is preferably a stable 4 to 11 membered non-aromatic monocyclic, bicyclic, bridged or spiro group containing from 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur.
- heterocyclic groups include, but are not limited to, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, thiomorpholinyl, 2,7-diazaspiro[3.5]decane.
- heterocycloalkyl as a group or part of another group means consisting of 2 to 14 carbon atoms and 1 to 6 heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur.
- a heterocycloalkyl group may be a monocyclic, bicyclic, tricyclic or more cyclic ring system, which may include a bridged ring system or a spiro ring system; nitrogen and carbon in the heterocyclic group Or a sulfur atom can be optionally oxidized; the nitrogen atom can optionally be quaternized.
- the heterocycloalkyl group can be attached to the remainder of the molecule via a carbon atom or a hetero atom and through a single bond, which can include a cyclo- or a spiro ring.
- a heterocycloalkyl group is preferably a stable 4 to 11 membered saturated monocyclic, bicyclic, bridged or spiro group containing from 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur. More preferably, it is a stable 4- to 7-membered saturated monocyclic, bicyclic, bridged or spiro group containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur.
- heterocyclic groups include, but are not limited to, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, thiomorpholinyl, 2,7-diazaspiro[3.5]decane-7-yl, 2-oxa-6-azaspiro[3.3]heptane-6-yl, 2,5-diaza-bicyclo[2.2.1]heptan-2-yl, azetidinyl, tetrahydrogen Pyranyl, tetrahydrofuranyl, dioxycyclopentyl, decahydroisoquinolyl, imidazolidinyl, thiazolidinyl, isothiazolidinyl, isoxazolidinyl, octahydroindenyl, octahydroisoindole Base, pyrazolidinyl and the like.
- aryl as a group or part of another group means a conjugated hydrocarbon ring system group having 6 to 18 carbon atoms, preferably having 6 to 10 carbon atoms.
- an aryl group may be a monocyclic, bicyclic, tricyclic or more cyclic ring system, and may also be fused to a cycloalkyl or heterocyclic group as defined above, provided that the aryl group is via The atoms on the aromatic ring are connected to the rest of the molecule by a single bond.
- aryl groups include, but are not limited to, phenyl, naphthyl, anthryl, phenanthryl, anthracenyl, 2,3-dihydro-1H isodecyl, 2-benzoxazolinone, 2H-1,4 - benzoxazine-3(4H)-keto-7-yl and the like.
- arylalkyl refers to an alkyl group as defined above substituted with an aryl group as defined above.
- heteroaryl as a group or part of another group means having from 1 to 15 carbon atoms (preferably having from 1 to 10 carbon atoms) and from 1 to 6 selected from nitrogen in the ring. a 5- to 16-membered conjugated ring system of a hetero atom of oxygen and sulfur. Unless otherwise specifically indicated in the specification, a heteroaryl group may be a monocyclic, bicyclic, tricyclic or more cyclic ring system, and may also be fused to a cycloalkyl or heterocyclic group as defined above, provided that The aryl group is attached to the remainder of the molecule via a single bond through an atom on the aromatic ring.
- the nitrogen, carbon or sulfur atom in the heteroaryl group can be optionally oxidized; the nitrogen atom can optionally be quaternized.
- the heteroaryl group is preferably a stable 5- to 12-membered aromatic group containing from 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably from 1 to 4 A stable 5- to 10-membered aromatic group derived from a hetero atom of nitrogen, oxygen, and sulfur or a 5- to 6-membered aromatic group containing 1-3 hetero atoms selected from nitrogen, oxygen, and sulfur.
- heteroaryl groups include, but are not limited to, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, Benzimidazolyl, benzopyrazolyl, fluorenyl, furyl, pyrrolyl, triazolyl, tetrazolyl, triazinyl, pyridazinyl, isodecyl, oxazolyl, isoxazolyl , fluorenyl, quinolyl, isoquinolyl, diaza naphthyl, naphthyridinyl, quinoxalinyl, pteridinyl, oxazolyl, porphyrin, phenanthryl, phenanthroline, acridine Base, phenazinyl
- heteroarylalkyl refers to an alkyl group as defined above which is substituted by a heteroaryl group as defined above.
- “optionally” or “optionally” means that the subsequently described event or condition may or may not occur, and that the description includes both the occurrence and non-occurrence of the event or condition.
- “optionally substituted aryl” means that the aryl group is substituted or unsubstituted, and the description includes both the substituted aryl group and the unsubstituted aryl group.
- a chemical moiety refers to a particular fragment or functional group in a molecule.
- a chemical moiety is generally considered to be a chemical entity that is embedded or attached to a molecule.
- the compounds of the present invention are intended to include E- and Z-geometric isomers unless otherwise stated.
- Tautomer refers to an isomer formed by the transfer of a proton from one atom of a molecule to another atom of the same molecule.
- the compounds of the invention may contain one or more chiral carbon atoms, and thus may give rise to enantiomers, diastereomers, and other stereoisomeric forms.
- Each chiral carbon atom can be defined as (R)- or (S)- based on stereochemistry.
- the invention is intended to include all possible isomers, as well as racemic and optically pure forms thereof.
- the preparation of the compounds of the invention may employ racemates, diastereomers or enantiomers as starting materials or intermediates.
- Optically active isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as by crystallization and chiral chromatography.
- pharmaceutically acceptable salt includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
- “Pharmaceutically acceptable acid addition salt” means a salt formed with an inorganic or organic acid which retains the bioavailability of the free base without any other side effects.
- Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, and the like; organic acid salts include, but are not limited to, formate, acetate, 2,2 dichloroacetate, Trifluoroacetate, propionate, hexanoate, octanoate, decanoate, undecylenate, glycolate, gluconate, lactate, sebacate, adipic acid Salt, glutarate, malonate, oxalate, maleate, succinate, fumarate, tartrate, citrate, palmitate, stearate, oleate, Citrate, laurate, malate, glutamate, pyroglutamate, aspartate, benzoate, methanesulf
- “Pharmaceutically acceptable base addition salt” refers to a salt formed with an inorganic or organic base which is capable of retaining the biological effectiveness of the free acid without other side effects.
- Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like.
- Preferred inorganic salts are ammonium, sodium, potassium, calcium and magnesium salts.
- Salts derived from organic bases include, but are not limited to, the following salts: primary amines, secondary amines and tertiary amines, substituted amines, including naturally substituted amines, cyclic amines, and basic ion exchange resins.
- ammonia isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, bicyclo Hexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, hydrazine, piperazine, piperazine Pyridine, N-ethylpiperidine, polyamine resin, and the like.
- Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
- pharmaceutical composition refers to a formulation of a compound of the invention and a medium generally accepted in the art for delivery of a biologically active compound to a mammal, such as a human.
- the medium includes a pharmaceutically acceptable carrier.
- the purpose of the pharmaceutical composition is to promote the administration of the organism, thereby facilitating the absorption of the active ingredient and thereby exerting biological activity.
- pharmaceutically acceptable refers to a substance (such as a carrier or diluent) that does not affect the biological activity or properties of the compound of the invention, and is relatively non-toxic, ie, the substance can be administered to an individual without causing undesirable organisms. The reaction or in an undesirable manner interacts with any of the components contained in the composition.
- pharmaceutically acceptable excipients include, but are not limited to, any adjuvants, carriers, excipients, glidants, supplements approved by the relevant government authorities for acceptable use by humans or domestic animals. Sweeteners, diluents, preservatives, dyes/colorants, flavoring agents, surfactants, wetting agents, dispersing agents, suspending agents, stabilizers, isotonic agents, solvents or emulsifiers.
- the "tumor” of the present invention includes, but is not limited to, brain tumors including neuroblastoma, glioma, glioblastoma and astrocytoma, sarcoma, melanoma, articular chondrocarcinoma, cholangiocarcinoma, leukemia, gastrointestinal Lymphoma, disseminated large B-cell lymphoma, follicular lymphoma and other lymphoma, histiocytic lymphoma, non-small cell lung cancer, small cell lung cancer, pancreatic cancer, lung squamous cell carcinoma, lung adenocarcinoma, breast cancer, prostate Cancer, liver cancer, skin cancer, epithelial cell carcinoma, cervical cancer, ovarian cancer, colon cancer, nasopharyngeal cancer, brain cancer, bone cancer, esophageal cancer, melanoma, kidney cancer, oral cancer, multiple myeloma, mesothelioma ,
- preventing include the possibility of reducing the occurrence or progression of a disease or condition by a patient.
- treatment and other similar synonyms as used herein includes the following meanings:
- an effective amount refers to at least one agent or compound that, after administration, is sufficient to alleviate one or more symptoms of the disease or condition being treated to some extent.
- the amount can be a reduction and/or alleviation of signs, symptoms or causes, or any other desired change in the biological system.
- an "effective amount" for treatment is an amount of a composition comprising a compound disclosed herein that is required to provide a significant conditional relief effect in the clinic.
- An effective amount suitable for any individual case can be determined using techniques such as dose escalation testing.
- administering refers to a method of delivering a compound or composition to a desired site for biological action. These methods include, but are not limited to, oral routes, duodenal routes, parenteral injections (including intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion), topical administration, and rectal administration.
- parenteral injections including intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion
- topical administration and rectal administration.
- the techniques of administration of the compounds and methods described herein are well known to those skilled in the art, for example, in Goodman and Gilman, The Pharmacological Basis of Therapeutics, current ed.; Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, those discussed in Pa.
- the compounds and compositions discussed herein are administered orally.
- pharmaceutical combination means a pharmaceutical treatment obtained by mixing or combining more than one active ingredient, It includes both fixed and unfixed combinations of active ingredients.
- fixed combination refers to the simultaneous administration of at least one compound described herein and at least one synergistic agent to a patient in the form of a single entity or a single dosage form.
- unfixed combination refers to the simultaneous administration, combination or sequential administration of at least one of the compounds described herein and at least one synergistic formulation to the patient in the form of separate entities. These are also applied to cocktail therapy, for example the administration of three or more active ingredients.
- the intermediate compound functional groups may need to be protected by a suitable protecting group.
- suitable protecting groups include trialkylsilyl or diarylalkylsilyl groups (e.g., tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl) , tetrahydropyranyl, benzyl, and the like.
- Suitable protecting groups for amino, mercapto and fluorenyl include t-butoxycarbonyl, benzyloxycarbonyl and the like.
- Suitable mercapto protecting groups include -C(O)-R" (wherein R" is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl and the like.
- Suitable carboxy protecting groups include alkyl, aryl or aralkyl esters.
- Protecting groups can be introduced and removed according to standard techniques known to those skilled in the art and as described herein. The use of protecting groups is described in detail in Greene, T. W. and P. G. M. Wuts, Protective Groups in Organi Synthesis, (1999), 4th Ed., Wiley.
- the protecting group can also be a polymeric resin.
- the starting materials used in the following examples can be purchased from chemical distributors such as Aldrich, TCI, Alfa Aesar, Bied, Angie, etc., or can be synthesized by known methods.
- the ice bath means -5 degrees Celsius to 0 degrees Celsius
- the room temperature means 10 degrees Celsius to 30 degrees Celsius.
- the reflux temperature generally means the solvent reflux temperature under normal pressure of the solvent.
- the reaction overnight means that the time is 8-15 hours.
- the specific operating temperatures were not limited and were carried out at room temperature.
- the separation and purification of the intermediate and final product is carried out by normal phase or reverse phase chromatography column or other suitable method.
- the normal phase flash column uses ethyl acetate and n-hexane or methanol and dichloromethane as the mobile phase.
- Reversed phase preparative high pressure liquid chromatography (HPLC) was performed on a C18 column with UV 214 nm and 254 nm.
- the mobile phase was A (water and 0.1% formic acid), B (acetonitrile) or mobile phase A (water and 0.1% carbonic acid). Ammonium hydroxide), B (acetonitrile).
- LCMS instrument Pump Agilent 1260 UV detector: Agilent 1260 DAD Mass Spectrometer API 3000.
- Step 1 (R)-1-((R)-1,1-dimethylethylsulfonamido)-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
- Step 2 (R)-2-Methyl-N-((R)-8-azaspiro[4.5]decan-1-yl)propane-2-sulfinamide (C-1A)
- Step 1 4-(2-(Benzyloxy)-1-hydroxyethyl)piperidine-1,4-dicarboxylic acid 1-tert-butyl-4-methyl ester
- Step 2 4-(2-(Benzyloxy)-1-hydroxyethyl)-4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester
- Step 3 4-(1,2-Dihydroxyethyl)-4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester
- Step 4 4-Hydroxy-2-oxa-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
- Step 5 4-carbonyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
- Step 6 (S)-4-((R)-1,1-dimethylethylsulfinamido)-2-oxa-8-azaspiro[4.5]decane-8-carboxylic acid Butyl ester
- Step 7 (R)-2-Methyl-N-((S)-2-oxa-8-azaspiro[4.5]decane-4-yl)propane-2-sulfinamide (C-1H )
- Step 3 4-Hydroxy-4-(1-methoxyprop-1,2-dien-1-yl)piperidine-1-carboxylic acid tert-butyl ester
- Step 4 4-methoxy-1-oxa-8-azaspiro[4.5]decane-3-ene-8-carboxylic acid tert-butyl ester
- Step 5 4-carbonyl-1-oxa-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
- Steps 6 and 7 Synthesis of (R)-2-methyl-N-((R)-1-oxa-8-azaspiro[4.5]decane-4-yl)propane-2-sulfinamide (C-1I)
- Step 1 (S)-2-((tert-Butyldimethylsilyl)oxy)propionic acid ethyl ester
- Step 3 4-((2S)-2-((tert-Butyldimethylsilyl)oxy)-1-hydroxypropyl)piperidine-1,4-dicarboxylic acid 1-(tert-butyl)
- Step 4 ((2S)-2-((tert-Butyldimethylsilyl)oxy)-1-hydroxypropyl)-4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester
- Step 5 4-((2S)-1,2-Dihydroxypropyl)-4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester
- Step 7 (S)-tert-Butyl-3-methyl-4-carbonyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylate
- Step 8 (3S,4S)-4-((R)-tert-butylsulfinyl)amino)-3-methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylic acid Tert-butyl ester
- Step 9 (R)-2-Methyl-N-((3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-yl)propane-2- Sulfinamide (C-1J)
- Step 1 2-methyl-1-carbonyl-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
- Step 1 3,3-Dimethyl-4-carbonyl-1-oxa-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
- reaction mixture was diluted with ethyl acetate (150 mL) and washed with saturated NaHCO 3 solution (150 mL) quenched, extracted with ethyl acetate (2 ⁇ 300mL). The combined organic phases were dried over anhydrous sodium sulfate. Filter and concentrate under reduced pressure.
- Step 2 (S)-4-((tert-butylsulfinyl)imino)-3,3-dimethyl-1-oxa-8-azaspiro[4.5]decane-8-carboxylic acid Butyl ester
- Step 3 (R)-4-(((R)-tert-butylsulfinyl)amino)-3,3-dimethyl-1-oxa-8-azaspiro[4.5]decane-8 - tert-butyl formate and (S)-4-(((R)-tert-butylsulfinyl)amino)-3,3-dimethyl-1-oxa-8-azaspiro[4.5] ⁇ Alkyl-8-carboxylic acid tert-butyl ester)
- Step 4 (R)-N-((R)-3,3-Dimethyl-1-oxa-8-azaspiro[4.5]decane-4-yl)-2-methylpropane-2 - sulfinamide (C-1L)
- Step 1 4-Allyl-4-formylpiperidine-1-carboxylic acid tert-butyl ester
- Step 2 4-Allyl-4-(1-hydroxyallyl)piperidine-1-carboxylic acid tert-butyl ester (C-1N-c)
- Step 3 4-Allyloxy-4-allylpiperidine-1-carboxylic acid tert-butyl ester
- Step 4 1-carbonyl-8-azaspiro[4.5]decane-2-ene-8-carboxylic acid tert-butyl ester
- Step 5 3-methyl-1-carbonyl-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
- Steps 6 and 7 (R)-2-Methyl-N-((1R)-3-methyl-8-azaspiro[4.5]decane-1-yl)propane-2-sulfinamide (C -1N)
- Step 1 (R)-3-((tert-Butyldimethylsilyl)oxy)-1-carbonyl-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
- Step 2 (1R,3R)-3-((tert-Butyldimethylsilyl)oxy)-1-((R)-1,1-dimethylethylsulfonamido)-8 -azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
- Step 3 (R)-N-((1R,3R)-3-hydroxy-8-azaspiro[4.5]decane-1-yl)-2-methylpropane-2-sulfinamide (C- 1O)
- Step 2 (1R,3R)-1-((tert-Butoxycarbonyl)amino)-3-hydroxy-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester (C-1P-b)
- Step 3 (R)-1-((tert-Butoxycarbonyl)amino)-3-carbonyl-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
- Step 4 (R)-1-((tert-Butoxycarbonyl)amino)-3,3-difluoro-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
- Step 4 (4-ethylpiperidin-4-yl)carbamic acid tert-butyl ester
- Step 5 (4-ethylpiperidin-4-yl)carbamic acid tert-butyl ester (C-3A)
- Step 2 1-Benzoyl-((4-methylpiperidin-4-yl)methyl)carbamic acid tert-butyl ester
- Step 3 ((4-Methylpiperidin-4-yl)methyl)carbamic acid tert-butyl ester (C-4A)
- Step 1 4-Cyano-4-phenylpiperidine-1-carboxylic acid tert-butyl ester
- Step 2 4-(Aminomethyl)-4-phenylpiperidine-1-carboxylic acid tert-butyl ester
- Step 1 (6-chloropyridin-2-yl)carbamic acid tert-butyl ester
- 6-chloropyridin-2-amine 8 g, 62.2 mmol
- THF 80 mL
- the mixture was stirred at 0 ° C for 10 min then NaHDMS (124.4 mL, 1.0 M in THF), then a solution of di-tert-butyl dicarbonate (16.3 g, 74.7 mmol) in tetrahydrofuran (50 mL) was slowly added at 0 ° C, and the reaction was continued at 0 ° C for 4 hours. After completion of the reaction, H 2 O (40mL), then extracted with EtOAc (3 x 100mL).
- Step 2 (5,6-Dichloropyridin-2-yl)carbamic acid tert-butyl ester
- Step 3 (5,6-Dichloro-4-iodopyridin-2-yl)carbamic acid tert-butyl ester
- Step 4 Methyl 3-((6-((tert-butoxycarbonyl)amino)-2,3-dichloropyridin-4-yl)thio)propanoate
- Example 17 According to the synthesis method of Example 17, the following intermediates were reacted to obtain the following intermediates F-1B, F-1C, F-1D, F-1E, F-1F, F-1G, F-1H, F-1I. , F-1J, F-1K, F-1L, F-1M, F-1N, F-1O, F-1P.
- Step 1 3-((6-((tert-Butoxycarbonyl)amino)-3-chloro-2-methylpyridin-4-yl)thio)propanoate
- Step 1 (1-(8-Iodoimidazo[1,2-c]pyrimidin-5-yl)-4-methylpiperidin-4-yl)carbamic acid tert-butyl ester
- 5-chloro-8-iodoimidazo[1,2-c]pyrimidine E1 50 mg, 0.18 mmol
- (4-methylpiperidin-4-yl) was sequentially added to a dry 50 mL one-necked flask.
- tert-Butyl carbamate 77 mg, 0.36 mmol
- DIEA 46 mg, 0.36 mmol
- NMP 5 mL
- Step 1 (1-(8-((2,3-Dichlorophenyl)thio)imidazo[1,2-c]pyrimidin-5-yl)pyrrolidin-3-yl)carbamic acid tert-butyl ester
- Step 2 Compound 1-(8-((2,3-dichlorophenyl)thio)imidazo[1,2-c]pyrimidin-5-yl)pyrrolidin-3-amine
- Example 37 Compound (S)-8-(8-((2,3-dichlorophenyl)thio)imidazo[1,2-c]pyrimidin-5-yl)-2-oxa-8 Synthesis of aza-spiro[4.5]decane-4-amine
- Step 1 (R)-N-((S)-8-(8-((2,3-dichlorophenyl)thio)imidazo[1,2-c]pyrimidin-5-yl)-2 -oxa-8-azaspiro[4.5]decane-4-yl)-2-methylpropane-2-sulfinamide
- Step 2 (S)-8-(8-((2,3-Dichlorophenyl)thio)imidazo[1,2-c]pyrimidin-5-yl)-2-oxa-8-nitrogen Heterospiro[4.5]decane-4-amine
- Example 46 Compound (R)-8-(8-((2,3-dichlorophenyl)thio)imidazo[1,2-c]pyrimidin-5-yl)-N-methyl-8 Synthesis of aza-spiro[4.5]decane-1-amine
- Step 1 (R)-N-((R)-8-(8-((2,3-dichlorophenyl)thio)imidazo[1,2-c]pyrimidin-5-yl)-8 -azaspiro[4.5]decane-1-yl)-2-methylpropane-2-sulfinamide
- Step 2 (R)-N-((R)-8-(8-((2,3-dichlorophenyl)thio)imidazo[1,2-c]pyrimidin-5-yl)-8 -azaspiro[4.5]decane-1-yl)-N,2-dimethylpropane-2-sulfinamide
- Step 3 (R)-8-(8-((2,3-Dichlorophenyl)thio)imidazo[1,2-c]pyrimidin-5-yl)-N-methyl-8-nitrogen Hetero-spiro[4.5]decane-1-amine
- Step 1 (R)-N-((R)-8-(8-Iodoimidazo[1,2-c]pyrimidin-5-yl)-8-azaspiro[4.5]decane-1-yl )-2-methylpropane-2-sulfonamide
- Step 2 (R)-N-((R)-8-(8-((2,3-dichlorophenyl)thio)imidazo[1,2-c]pyrimidin-5-yl)-8 -azaspiro[4.5]decane-1-yl)-2-methylpropane-2-sulfinamide
- Step 3 (R)-8-(8-((2,3-Dichlorophenyl)thio)imidazo[1,2-c]pyrimidin-5-yl)-8-azaspiro[4.5] Decane-1-amine
- reaction liquid was distilled under reduced pressure, and the obtained crude product was purified by reverse-phase high-performance liquid chromatography to give the product (R)-8-(8-((2,3-dichlorophenyl)thio)imidazo[1,2-c Pyrimidine-5-yl)-8-azaspiro[4.5]decane-1-amine (25 mg, yield: 51%).
- Example 71 Compound (R)-N-(3-((5-(1-amino-8-azaspiro[4.5]decane-8-yl)imidazo[1,2-c]pyrimidine-8 Synthesis of -yl)thio)-2-chlorophenyl)acrylamide
Abstract
Description
Claims (25)
- 一种式(I)所示的嘧啶并环化合物、其药学上可接受的盐、水合物、前药、立体异构体或其溶剂化物,其中,Z 1和Z 2同时为CH,或者,Z 1和Z 2中的一个为N,另一个为CH;X独立地为S或不存在;Y独立地为C或N;n独立地为0、1或2;R 1独立地为0-4个R 1a取代的苯基、0-4个R 1a取代的含有1-4个氮杂芳基、0-4个R 1a取代的萘基、0-4个R 1a取代的含有1-4个氮杂萘芳基、0-4个R 1a取代或未取代的苯并杂环基、0-4个R 1a取代或未取代的含有1-4个氮杂芳并环基、0-4个R 1a取代的含有1-4个N、NR 1b、O或S(O)m杂原子的杂芳基、R 1c取代或未取代的C 1-8烷基、或者、R 1c取代或未取代的C 1-8卤代烷基;其中m选自0、1和2;R 2a、R 2b、R 3a和R 3b独立地为氢、或R 1a1取代或未取代的C 1-4烷基;当Y=N时,R 4独立地为氢、或R 1a1取代或未取代的C 1-4烷基;R 5不存在;当Y=C时,R 4和R 5独立地为氢、芳基、C 1-4烷基、C 1-4烷氧基、-O-C 1-4烷基、氨基、C 1-4烷基取代氨基或-O-C 1-4烷基取代氨基,或者,R 4和R 5与Y一起形成0-3个R 4a取代的3至7元饱和或部分不饱和的螺环,该环可任选含有1-3个独立地选自N、C(=O)和/或O杂原子或基团;或者,R 4和R 5与Y一起形成0-3个R 4a取代的3至7元环烷基,或,0-3个R 4a取代的3至7元杂环烷基;所述的3至7元杂环烷基中,杂原子选自N、O和S中的一种或多种,所述杂原子的个数为1-3个;或者,R 2a、R 2b、R 3a、R 3b、R 4和R 5中相邻的两个基团与连接的碳和Y一起形成0-3个R 4a取代的3至7元环烷基,或,0-3个R 4a取代的3至7元杂环烷基;所述的3至7元杂环烷基中,杂原子选自N、O和S中的一种或多种,所述杂原子的个数为1-3个;R 1a独立地为卤素、R 1a1取代或未取代的C 1-4烷氧基、R 1a1取代或未取代的C 1-4烷基、三氟甲基、-C(=O)OR 1a2、-NR 1a2R 1a3、-NHC(=O)R 1a4、或R 1a1取代或未取代的C 3-8环烷基、;R 1b独立地为氢、或、R 1a1取代或未取代的C 1-4烷基;R 1c独立地为氢、-C(=O)OR 1a2、或、R 1a1取代或未取代的C 1-4烷基;R 4a独立地为氢、卤素、R 1a1取代或未取代的C 1-4烷氧基、R 1a1取代或未取代的C 1-4烷基、羟基、氨基或C 1-4烷基氨基;R 1a1独立地为卤素或C 1-4烷基;R 1a2和R 1a3独立地为氢或C 1-4烷基;R 1a4独立地为C 1-4烷基、取代或未取代的烯基、一个或两个R 1a1取代的-NHC(=O)H、一个或两个R 1a1取代的-C(=O)NH 2、酰胺、C 3-12单或多杂环基、或者、取代的C 3-12单或多杂环基;所述的取代的C 3-12单或多杂环基中的取代为独立地被一个或多个选自以下的取代基取代:R 1a1、-OH和=O;当所述的取代为多个时,所述的取代基相同或不同。
- 如权利要求1所述的式(I)所示的嘧啶并环化合物、其药学上可接受的盐、水合物、前药、立体异构体或其溶剂化物,其特征在于,所述的0-4个R 1a取代的苯基为 其中,o独立地为0、1、2、3或4,且R 1aa和R 1ab的总数为0-4个,R 1aa和R 1ab的定义同R 1a所述;和/或,所述的0-4个R 1a取代的含有1-4个氮杂芳基为 其中,o独立地为0、1、2、3或4,且R 1aa和R 1ab的总数为0-4个,R 1aa和R 1ab的定义同R 1a所述; 为所述的含有1-4个氮杂芳基;和/或,所述的0-4个R 1a取代的含有1-4个氮杂萘芳基为 其中,o为0、1、2、3或4,且R 1aa和R 1ab的总数为0-4个,R 1aa和R 1ab的定义同R 1a所述; 为所述的含有1-4个氮杂芳基;和/或,所述的0-4个R 1a取代或未取代的苯并杂环基为 其中,G独立地为C、C(=O)、N、S或O杂原子或基团,o为0、1、2、3或4,且R 1aa和R 1ab的总数 为0-4个,R 1aa和R 1ab的定义同R 1a所述; 为所述的苯并杂环基;和/或,所述的0-4个R 1a取代或未取代的含有1-4个氮杂芳并环基为 其中,o为0、1、2、3或4,且R 1aa和R 1ab的总数为0-4个,R 1aa和R 1ab的定义同R 1a所述; 为所述的含有1-4个氮杂芳并环基,其中 为含有1-4个氮杂芳基, 为含有1-4个N、NR 1b、O或S(O)m杂原子的杂芳基;和/或,所述的0-4个R 1a取代的含有1-4个N、NR 1b、O或S(O)m杂原子的杂芳基为 其中,o为0、1、2、3或4,且R 1aa和R 1ab的总数为0-4个,R 1aa和R 1ab的定义同R 1a所述; 为含有1-4个N、NR 1b、O或S(O)m杂原子的杂芳基;和/或,在R 1c取代或未取代的C 1-8烷基和R 1c取代或未取代的C 1-8卤代烷基中,所述的C 1-8烷基和C 1-8卤代烷基中的C 1-8烷基独立地为甲基、乙基、正丙基、异丙基、正丁基、叔丁基、仲丁基、异丁基、正戊基、1-乙基-丙基、1-甲基-丁基、2-甲基-1-丁基、3-甲基-1-丁基、新戊基、3-甲基-2-丁基、叔戊基、正己基或异己基;和/或,在R 1c取代或未取代的C 1-8卤代烷基中,所述的C 1-8卤代烷基中的卤为氟、氯、溴或碘;和/或,在R 1c取代或未取代的C 1-8卤代烷基中,所述的C 1-8卤代烷基中的卤代的个数为1、2、3、4、5或6;和/或,在R 1a1取代或未取代的C 1-4烷基中,所述的C 1-4烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当R 4和/或R 5为芳基时,所述的芳基为C 6-C 10芳基;和/或,当R 4和/或R 5为C 1-4烷基、-O-C 1-4烷基、C 1-4烷基取代氨基、或、-O-C 1-4烷基取代氨基 时,所述的C 1-4烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当R 4和/或R 5为C 1-4烷氧基时,所述的C 1-4烷氧基为甲基氧基、乙基氧基、正丙基氧基、异丙基氧基、正丁基氧基、异丁基氧基、仲丁基氧基或叔丁基氧基;和/或,在R 4和R 5与Y一起形成0-3个R 4a取代的3至7元环烷基中,所述的3至7元环烷基为环丁基、环戊基或环己基;和/或,在R 4和R 5与Y一起形成0-3个R 4a取代的3至7元杂环烷基中,所述的3至7元杂环烷基为5-6元杂环烷基,所述的5-6元杂环烷基中,杂原子选自N、O和S中的一种或多种,所述杂原子的个数为1-2个;和/或,当R 1a,R 1a1和R 4a中的一个或多个独立地为卤素时,所述的卤素为氟、氯、溴或碘;和/或,在R 1a1取代或未取代的C 1-4烷氧基中,所述的C 1-4烷氧基为甲基氧基、乙基氧基、正丙基氧基、异丙基氧基、正丁基氧基、异丁基氧基、仲丁基氧基或叔丁基氧基;和/或,在R 1a1取代或未取代的C 3-8环烷基中,所述的C 3-8环烷基为环丙基、环丁基、环戊基、环己基、环庚基或环辛基;和/或,当R 1a1、R 1a2、R 1a3和R 1a4中的一个或多个独立地为C 1-4烷基时,所述的C 1-4烷基可为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当R 4a为C 1-4烷基氨基时,所述的C 1-4烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,在取代或未取代的烯基中,所述的烯基为C 2-C 10烯基;和/或,所述的酰胺为-C(=O)NH 2或-NHC(=O)H;和/或,所述的C 3-12单或多杂环基中、或者、取代的C 3-12单或多杂环基中的C 3-12单或多杂环基中,杂原子选自氮、氧和硫中的一种或多种,杂原子个数为1-4个。
- 和/或,在所述的0-4个R 1a取代的含有1-4个氮杂芳基中,所述的含有1-4个氮杂芳基为吡啶基、嘧啶基、吡嗪基或哒嗪基;和/或,在所述的0-4个R 1a取代的含有1-4个氮杂萘芳基中,所述的含有1-4个氮杂萘芳基为喹啉基;和/或,在所述的0-4个R 1a取代或未取代的苯并杂环基中,所述的苯并杂环基为2,3-二氢苯并呋喃基或吲哚啉基;和/或,在所述的0-4个R 1a取代或未取代的含有1-4个氮杂芳并环基中,所述的含有1-4个氮杂芳并环基为1H-吡咯并[2,3-b]吡啶;和/或,在所述的0-4个R 1a取代的含有1-4个N、NR 1b、O或S(O)m杂原子的杂芳基中,所述的含有1-4个N、NR 1b、O或S(O)m杂原子的杂芳基为咪唑基、噻唑基、噁唑基、噻二唑基或苯并噻唑基;和/或,当R 4和/或R 5为芳基时,所述的芳基为苯基或萘基,和/或,R 4和R 5中所述的C 1-4烷基取代氨基,或者,R 4a中所述的C 1-4烷基氨基为NH(CH 3);和/或,在取代或未取代的烯基中,所述的烯基为乙烯基、1-丙烯基、烯丙基、丁-1-烯基、丁-2-烯基、戊-1-烯基或戊-1,4-二烯基;和/或,所述的-C(=O)OR 1a2为-C(=O)OCH 3;和/或,所述的NR 1a2R 1a3为-NH 2或N(CH 3) 2;和/或,所述的两个R 1a1取代的-C(=O)NH 2为-C(=O)N(CH 3) 2;和/或,所述的C 3-12单或多杂环基、或者、取代的C 3-12单或多杂环基中的C 3-12单或多杂环基为单环或二环杂环基,杂原子选自氮、氧和硫中的一种或多种,杂原子个数为1-2个。
- 和/或,当Y=C、R 4和R 5与Y一起形成0-3个R 4a取代的3至7元环烷基时,所述的0-3个R 4a取代的3至7元环烷基为 其中,p为0、1、2或3;或者,当Y=C、R 4和R 5与Y一起形成0-3个R 4a取代的3至7元杂环烷基时,所述的0-3个R 4a取代的3至7元杂环烷基为 其中,p为0、1、2或3;
-
- 如权利要求1所述的式(I)所示的嘧啶并环化合物、其药学上可接受的盐、水合物、前药、立体异构体或其溶剂化物,其特征在于,所述的式(I)所示的嘧啶并环化合物中,Z 1、Z 2同时为C或其中之一为N;X独立地为S或不存在;Y独立地为C或N;n独立地为0、1或2;R 1独立地为0至4个R 1a取代的苯基、0至4个R 1a取代的含有1-4个氮杂芳基、0至4个R 1a取代的萘基、0至4个R 1a取代的含有1-4个氮杂萘芳基、0至4个R 1a取代或未取代的苯并杂环、0至4个R 1a取代或未取代的含有1-4个氮杂芳并环、0至4个R 1a取代的含有1-4个N、NR 1b、O或S(O)m等杂原子的杂芳环、R 1c取代或未取代的C 1-8烷基、R 1c取代或未取代的C 1-8卤代烷基;其中m选自0、1和2;R 1a独立地为卤素、R 1a1取代或未取代的C 1-4烷氧基、R 1a1取代或未取代的C 1-4烷基、三氟甲基、C(=O)OR 1a2、NR 1a2R 1a3、NHC(=O)R 1a4、R 1a1取代或未取代的C 3-8环烷基;R 1a1独立地为卤素或C 1-4烷基;R 1a2、R 1a3独立地为氢、C 1-4烷基;R 1a4独立地为C 1-4烷基、取代或未取代的烯基、酰胺、C 3-12单或多杂环;R 1b独立地为氢、R 1a1取代或未取代的C 1-4烷基;R 1c独立地为氢、-C(=O)OR 1a2、R 1a1取代或未取代的C 1-4烷基;R 2a、R 2b、R 3a和R 3b独立地为氢、R 1a1取代或未取代的C 1-4烷基;当Y=N时,R 4独立地为氢、R 1a1取代或未取代的C 1-4烷基;R 5不存在;当Y=C时,R 4、R 5独立地为氢、芳基、C 1-4烷基、C 1-4烷氧基、-O-C 1-4烷基、氨基、C 1-4烷基取代氨基、-O-C 1-4烷基取代氨基,或者R 4和R 5与Y一起形成0至3个R 4a取代的3至7元饱和或部分不饱和的螺环,该环可任选含有1至3个独立地选自N、C(=O)和/或O等杂原子或基团;R 4a独立地为氢、卤素、R 1a1取代或未取代的C 1-4烷氧基、R 1a1取代或未取代的C 1-4烷基、羟基、氨基、C 1-4烷基氨基。
- 如权利要求8所述的式(I)所示的嘧啶并环化合物、其药学上可接受的盐、水合物、前药、立体异构体或其溶剂化物,其特征在于,其中R 1选自以下结构:其中,o为0、1、2、3或4;环A为含有1至4个N原子的杂芳基;环B为含有1至4个N、S、O等杂原子的杂芳基;G独立地为C、C(=O)、N、S或O等杂原子或基团;R 1aa、R 1ab独立地为如权利要求1定义的R 1a;R 1ac独立地为R 1c取代或未取代的C 1-8烷基、R 1c取代或未取代的C 1-8卤代烷;和/或,R 2a、R 2b、R 3a和R 3b独立地为氢或甲基;和/或,当Y=N时,R 4独立地为氢或甲基;R 5不存在;和/或,当Y=C时,R 4和R 5独立地为氢、甲基、乙基、苯基、氨基、甲基氨基或乙基氨基;和/或,当Y=C时,R 4和R 5与Y一起形成的环选自以下结构:其中,p为0、1、2或3;R 4a如权利要求1定义。
- 一种如权利要求1-12任一项所述的式(I)所示的嘧啶并环化合物、其药学上可接受的盐、水合物、前药、立体异构体或其溶剂化物的同位素标记化合物,所述同位素选自 2H、 3H、 11C、 13C、 14C、 15N、 18F、 31P、 32P、 35S、 36Cl和 125I。
- 一种如权利要求1-12任一项所述的式(I)所示的嘧啶并环化合物的制备方法,其包括如下任一方案;方案一,其包括如下步骤:将如式A所示的卤代中间体化合物与化合物F进行如下所示的偶联反应后得到如式(I)所示的嘧啶并环化合物即可,反应方程式如下:其中,当X不存在时,化合物F表述R1的硼酸、硫醇或硫钠;当X为S时,化合物F为硫醇或硫钠;W 1代表卤素;方案二,其包括如下步骤:将如式B所示的中间体与如式C所示的胺进行如下所示的取代反应后得到如式(I)所示的嘧啶并环化合物,反应方程式如下:其中,W 2代表卤素;方案三,当如式(I)所示的嘧啶并环化合物为式(I-B)所示的嘧啶并环化合物时,其包括如下步骤:在酸性或碱性条件下,脱除如式I-B1所示的中间体的氨基保护基Pg得到如式(I-B)所示的嘧啶并环化合物,反应方程式如下:其中,R 4Pg、R 5Pg与连接碳一起,选自以下结构:R 4、R 5与连接碳一起,选自以下结构:Pg选自为保护基Boc、Ac或S(=O) tBu;p为0、1、2或3;方案四,当如式(I)所示的嘧啶并环化合物为式(I-C)所示的嘧啶并环化合物时,其包括如下步骤:将如式I-C1所示的中间体进行如下所示的氨基酰基化后得到如式(I-C)所示的嘧啶并环化合物,反应方程式如下:方案五,当如式(I)所示的嘧啶并环化合物为如式(I-A)所示的嘧啶并环化合物时,其包括如下步骤:将如式D所示的硫钠中间体化合物与卤代物R 1-W 1进行如下所示的偶联反应得到如式(I-A)所示的嘧啶并环化合物,反应方程式如下:
- 如权利要求15所述的如式A所示的化合物、如式B所示的化合物、如式D所示的化合物、如式E所示的化合物、如式C-1所示的化合物、如式C-2所示的化合物、如式C-3所示的化合物、如式C-4所示的化合、如式F-1所示的化合物、如式F-1c所示的化合物,其特征在于,其中,所述的如式A所示的化合物选自如下任一结构:所述的如式C-1所示的化合物选自如下任一结构:所述的如式C-2所示的化合物选自如下任一结构:所述的如式E所示的化合物选自如下任一结构:所述的如式B所示的化合物选自如下任一结构:所述的如式F-1所示的化合物选自如下任一结构:所述的如式F-1c所示的化合物选自如下任一结构:
- 一种药物组合物,包含如权利要求1-12任一项所述的式(I)所示的嘧啶并环化合物、其药学上可接受的盐、水合物、前药、立体异构体或其溶剂化物或权利要求13所述的同位素标记化合物、以及药学上可接受的辅料。
- 一种如权利要求1-12任一项所述的式(I)所示的嘧啶并环化合物、其药学上可接受的盐、水合物、前药、立体异构体或其溶剂化物、如权利要求13所述的同位素标记化合物或如权利要求20所述的药物组合物在制备预防和/或治疗与SHP2活性异常相关疾病或病症的药物方面的用途。
- 如权利要求21所述的用途,所述疾病或病症选自努南综合症、豹综合症、青少年髓单核细胞白血病、成神经细胞瘤、黑色素瘤、急性髓性白血病、乳腺癌、食道癌、肺癌、结肠癌、头癌、成神经细胞瘤、头颈的鳞状细胞癌、胃癌、间变性大细胞淋巴瘤或成胶质细胞瘤。
- 一种药物制剂,包含如权利要求1-12任一项所述的式(I)所示的嘧啶并环化合物、其药学上可接受的盐、水合物、前药、立体异构体或其溶剂化物或权利要求13所述的同位素标记化合物。
- 如权利要求23所述的药物制剂,所述药物制剂的给予方式选自:口服、舌下含服、皮下注射、静脉注射、肌肉注射、胸骨内注射、鼻部服用、局部表面给药或直肠给药;和/或,所述药物制剂每天单次服用或多次服用。
- 一种如权利要求1-12任一项所述的式(I)所示的嘧啶并环化合物、其药学上可接受的盐、水合物、前药、立体异构体或其溶剂化物或权利要求13所述的同位素标记化合物与其他药物联合使用的产品,所述其他药物选自:抗癌药、肿瘤免疫药物、抗过敏药、止吐药、镇痛药、细胞保护药物。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020543947A JP7335882B2 (ja) | 2018-02-13 | 2019-02-03 | ピリミジン縮合環式化合物及びその製造方法、並びに使用 |
US16/969,392 US11498930B2 (en) | 2018-02-13 | 2019-02-03 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof |
KR1020207026395A KR102614939B1 (ko) | 2018-02-13 | 2019-02-03 | 피리미딘-융합고리 화합물 및 그의 제조방법과 용도 |
AU2019222026A AU2019222026B2 (en) | 2018-02-13 | 2019-02-03 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof |
SG11202007740TA SG11202007740TA (en) | 2018-02-13 | 2019-02-03 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof |
EP19754599.9A EP3753941A4 (en) | 2018-02-13 | 2019-02-03 | PYRIMIDINE CONDENSED CYCLIC COMPOUND, METHOD FOR MANUFACTURING IT, AND USE THEREOF |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810144135.3 | 2018-02-13 | ||
CN201810144135.3A CN110156786B (zh) | 2018-02-13 | 2018-02-13 | 嘧啶并环化合物及其制备方法和应用 |
CN201810692211.4A CN110655520A (zh) | 2018-06-29 | 2018-06-29 | 嘧啶并环化合物及其制备方法和应用 |
CN201810692211.4 | 2018-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019158019A1 true WO2019158019A1 (zh) | 2019-08-22 |
Family
ID=67618898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/074685 WO2019158019A1 (zh) | 2018-02-13 | 2019-02-03 | 嘧啶并环化合物及其制备方法和应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11498930B2 (zh) |
EP (1) | EP3753941A4 (zh) |
JP (1) | JP7335882B2 (zh) |
KR (1) | KR102614939B1 (zh) |
AU (1) | AU2019222026B2 (zh) |
MA (1) | MA51845A (zh) |
SG (1) | SG11202007740TA (zh) |
WO (1) | WO2019158019A1 (zh) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020094104A1 (zh) * | 2018-11-07 | 2020-05-14 | 如东凌达生物医药科技有限公司 | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 |
US10844079B2 (en) | 2018-11-06 | 2020-11-24 | Etern Biopharma (Shanghai) Co., Ltd. | Spiro aromatic ring compound and application thereof |
US10851110B2 (en) | 2016-05-31 | 2020-12-01 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
CN112194652A (zh) * | 2020-11-30 | 2021-01-08 | 北京华氏开元医药科技有限公司 | 4-羟甲基-1h-吲哚类化合物、制备方法及应用 |
US10894797B2 (en) | 2018-09-18 | 2021-01-19 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors |
WO2021032004A1 (zh) * | 2019-08-22 | 2021-02-25 | 上海青煜医药科技有限公司 | 氮杂芳基化合物及其应用 |
CN112402385A (zh) * | 2020-11-30 | 2021-02-26 | 北京华氏开元医药科技有限公司 | 4-羟甲基-1h-吲哚类化合物药物制剂及其制备方法 |
US10934302B1 (en) | 2018-03-21 | 2021-03-02 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
US10954243B2 (en) | 2018-05-02 | 2021-03-23 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of PTPN11 |
WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
US11104675B2 (en) | 2018-08-10 | 2021-08-31 | Navire Pharma, Inc. | PTPN11 inhibitors |
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
WO2022089389A1 (zh) * | 2020-10-30 | 2022-05-05 | 赣江新区博瑞创新医药有限公司 | 杂环化合物及其制备方法、药物组合物和应用 |
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
WO2022269525A1 (en) | 2021-06-23 | 2022-12-29 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
WO2023060253A1 (en) | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
US11629145B2 (en) | 2016-10-24 | 2023-04-18 | D. E. Shaw Research, Llc | SHP2 phosphatase inhibitors and methods of use thereof |
US11673901B2 (en) | 2017-12-15 | 2023-06-13 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric SHP2 inhibitors |
US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
US11890281B2 (en) | 2019-09-24 | 2024-02-06 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of making and using the same |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL264186B1 (en) | 2016-07-12 | 2024-04-01 | Revolution Medicines Inc | 2,5-dimutomers of 3-methylpyrazines and 2,5,6-dimutomers of 3-methylpyrazines as allosteric SHP2 inhibitors |
CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
JP7240320B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ,インコーポレイテッド | アロステリックshp2阻害剤としてのピリジン化合物 |
KR20200070295A (ko) | 2017-10-12 | 2020-06-17 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘, 피라진 및 트리아진 화합물 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010114881A1 (en) * | 2009-04-01 | 2010-10-07 | Progenra Inc. | Anti-neoplastic compounds, compositions and methods |
CN102869666A (zh) * | 2010-03-10 | 2013-01-09 | 凯利普西斯公司 | 用于疾病治疗的组胺受体的杂环抑制剂 |
CN104350055A (zh) * | 2012-03-30 | 2015-02-11 | 新加坡科技研究局 | 作为mnk1和mnk2调节剂的二环杂芳基衍生物及其用途 |
WO2015107495A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
WO2017211303A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2018013597A1 (en) | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
MX2020006273A (es) * | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Compuestos policiclicos como inhibidores alostericos de shp2. |
EP3860717A1 (en) * | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
CN117143079A (zh) | 2018-11-06 | 2023-12-01 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
TW202039498A (zh) | 2018-11-30 | 2020-11-01 | 大陸商上海拓界生物醫藥科技有限公司 | 嘧啶並五員氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
-
2019
- 2019-02-03 KR KR1020207026395A patent/KR102614939B1/ko active IP Right Grant
- 2019-02-03 EP EP19754599.9A patent/EP3753941A4/en active Pending
- 2019-02-03 AU AU2019222026A patent/AU2019222026B2/en active Active
- 2019-02-03 SG SG11202007740TA patent/SG11202007740TA/en unknown
- 2019-02-03 JP JP2020543947A patent/JP7335882B2/ja active Active
- 2019-02-03 US US16/969,392 patent/US11498930B2/en active Active
- 2019-02-03 WO PCT/CN2019/074685 patent/WO2019158019A1/zh unknown
- 2019-02-03 MA MA051845A patent/MA51845A/fr unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010114881A1 (en) * | 2009-04-01 | 2010-10-07 | Progenra Inc. | Anti-neoplastic compounds, compositions and methods |
CN102869666A (zh) * | 2010-03-10 | 2013-01-09 | 凯利普西斯公司 | 用于疾病治疗的组胺受体的杂环抑制剂 |
CN104350055A (zh) * | 2012-03-30 | 2015-02-11 | 新加坡科技研究局 | 作为mnk1和mnk2调节剂的二环杂芳基衍生物及其用途 |
WO2015107495A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
CN105899491A (zh) * | 2014-01-17 | 2016-08-24 | 诺华股份有限公司 | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 |
CN105916845A (zh) * | 2014-01-17 | 2016-08-31 | 诺华股份有限公司 | 用于抑制shp2活性的n-氮杂螺环烷取代的n-杂芳基化合物和组合物 |
WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
WO2017211303A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2018013597A1 (en) | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
Non-Patent Citations (7)
Title |
---|
"Chiral Separations, Methods and Protocols", METHODS IN MOLECULAR BIOLOGY, vol. 243, 2004 |
"VOGEL'S ENCYCLOPEDIA OF PRACTICAL ORGANIC CHEMISTRY", vol. 5, 1991, LONGMAN SCIENTIFIC AND TECHNICAL LTD., pages: 809 - 816 |
A.M. STALCUP: "Chiral Separations", ANNU. REV. ANAL. CHEM., vol. 3, 2010, pages 341 - 63 |
GREENETWPG WUTS: "The Pharmacological Basis of Therapeutics", 1999, MACK PUBLISHING CO |
HELLER, ACC. CHEM. RES., vol. 23, 1990, pages 128 |
HUANG, YING ET AL.: "Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 6, 16 January 2017 (2017-01-16), pages 2215 - 2226, XP002772151, ISSN: 1520-4804 * |
NATURE, vol. 535, 2016, pages 148 - 152 |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
US11840536B2 (en) | 2016-05-31 | 2023-12-12 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
US10851110B2 (en) | 2016-05-31 | 2020-12-01 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
US11629145B2 (en) | 2016-10-24 | 2023-04-18 | D. E. Shaw Research, Llc | SHP2 phosphatase inhibitors and methods of use thereof |
US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
US11673901B2 (en) | 2017-12-15 | 2023-06-13 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric SHP2 inhibitors |
US10934302B1 (en) | 2018-03-21 | 2021-03-02 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
US11932643B2 (en) | 2018-05-02 | 2024-03-19 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of PTPN11 |
US10954243B2 (en) | 2018-05-02 | 2021-03-23 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of PTPN11 |
US11104675B2 (en) | 2018-08-10 | 2021-08-31 | Navire Pharma, Inc. | PTPN11 inhibitors |
US11945815B2 (en) | 2018-08-10 | 2024-04-02 | Navire Pharma, Inc. | PTPN11 inhibitors |
US11518772B2 (en) | 2018-09-18 | 2022-12-06 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors |
US11459340B2 (en) | 2018-09-18 | 2022-10-04 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors |
US11034705B2 (en) | 2018-09-18 | 2021-06-15 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors |
US10894797B2 (en) | 2018-09-18 | 2021-01-19 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors |
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
US11685748B2 (en) | 2018-11-06 | 2023-06-27 | Etern Biopharma (Shanghai) Co., Ltd. | Spiro aromatic ring compound and application thereof |
US10844079B2 (en) | 2018-11-06 | 2020-11-24 | Etern Biopharma (Shanghai) Co., Ltd. | Spiro aromatic ring compound and application thereof |
WO2020094104A1 (zh) * | 2018-11-07 | 2020-05-14 | 如东凌达生物医药科技有限公司 | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 |
AU2020332462B2 (en) * | 2019-08-22 | 2023-08-17 | Shanghai Blueray Biopharma Co., Ltd. | Azaheteroaryl compound and application thereof |
CN112409385A (zh) * | 2019-08-22 | 2021-02-26 | 上海青煜医药科技有限公司 | 氮杂芳基化合物及其应用 |
WO2021032004A1 (zh) * | 2019-08-22 | 2021-02-25 | 上海青煜医药科技有限公司 | 氮杂芳基化合物及其应用 |
US11890281B2 (en) | 2019-09-24 | 2024-02-06 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of making and using the same |
WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
US11168102B1 (en) | 2019-11-08 | 2021-11-09 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
WO2022089389A1 (zh) * | 2020-10-30 | 2022-05-05 | 赣江新区博瑞创新医药有限公司 | 杂环化合物及其制备方法、药物组合物和应用 |
CN112402385B (zh) * | 2020-11-30 | 2022-04-01 | 北京华氏开元医药科技有限公司 | 4-羟甲基-1h-吲哚类化合物药物制剂及其制备方法 |
CN112402385A (zh) * | 2020-11-30 | 2021-02-26 | 北京华氏开元医药科技有限公司 | 4-羟甲基-1h-吲哚类化合物药物制剂及其制备方法 |
CN112194652A (zh) * | 2020-11-30 | 2021-01-08 | 北京华氏开元医药科技有限公司 | 4-羟甲基-1h-吲哚类化合物、制备方法及应用 |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
WO2022269525A1 (en) | 2021-06-23 | 2022-12-29 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
WO2023060253A1 (en) | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JP7335882B2 (ja) | 2023-08-30 |
SG11202007740TA (en) | 2020-09-29 |
EP3753941A1 (en) | 2020-12-23 |
KR102614939B1 (ko) | 2023-12-19 |
JP2021513555A (ja) | 2021-05-27 |
AU2019222026B2 (en) | 2022-05-12 |
AU2019222026A1 (en) | 2020-10-01 |
KR20200120713A (ko) | 2020-10-21 |
EP3753941A4 (en) | 2021-09-01 |
US11498930B2 (en) | 2022-11-15 |
US20210053989A1 (en) | 2021-02-25 |
MA51845A (fr) | 2020-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019158019A1 (zh) | 嘧啶并环化合物及其制备方法和应用 | |
CN110156786B (zh) | 嘧啶并环化合物及其制备方法和应用 | |
CN111153901B (zh) | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 | |
EP3712151B1 (en) | (s)-1'-(8-((2-amino-3-chloropyridin-4-yl)thio)imidazo[1,2-c]pyrimidin-5-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidine]-5-amine as shp2 inhibitor for the treatment of cancer | |
EP3035800A1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
EP2815750A1 (en) | 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors | |
TW201605866A (zh) | 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物 | |
WO2021115457A9 (zh) | 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用 | |
WO2016192630A1 (zh) | 一类具有激酶抑制活性的化合物、制备方法和用途 | |
CN113527299B (zh) | 一类含氮稠环类化合物、制备方法和用途 | |
WO2022134641A1 (zh) | 芳香杂环类化合物、药物组合物及其应用 | |
CN110655520A (zh) | 嘧啶并环化合物及其制备方法和应用 | |
CN111518100A (zh) | 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用 | |
WO2022089406A1 (zh) | 含氮稠杂环类化合物及其制备方法和应用 | |
CN109790160B (zh) | 吡啶并五元芳香环类化合物、其制备方法及用途 | |
AU2014365915C1 (en) | Tetrahydro-tetrazolo[1,5-a]pyrazines as ROR-gamma inhibitors | |
JP7406008B2 (ja) | Cdk9阻害剤としての多環式アミド系誘導体、その調製方法及び用途 | |
WO2023125121A1 (zh) | 一类三并环化合物、其制备方法及用途 | |
WO2023137634A1 (zh) | 三并环化合物、其制备、药物组合物及应用 | |
TW202312995A (zh) | 氮雜芳基化合物、其製備方法及應用 | |
US20240109868A1 (en) | Ep300/cbp modulator, preparation method therefor and use thereof | |
WO2023116763A1 (zh) | 一种哒嗪类化合物、其药物组合物及应用 | |
CN117659023A (zh) | 吡啶乙酰胺类衍生物、包含其的药物组合物及其医药用途 | |
CN116903610A (zh) | 杂环稠合的吡啶类化合物及其药物组合物和用途 | |
EP4293029A1 (en) | Azaheteroaryl compound, preparation method therefor, and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19754599 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020543947 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207026395 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019754599 Country of ref document: EP Effective date: 20200914 |
|
ENP | Entry into the national phase |
Ref document number: 2019222026 Country of ref document: AU Date of ref document: 20190203 Kind code of ref document: A |